Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2020 shares
Entity Incorporation, State or Country Code	DE
Document Type	10-Q
Document Quarterly Report	true
Entity File Number	001-01136
Entity Registrant Name	BRISTOL MYERS SQUIBB CO
Entity Address, Address Line One	430 E. 29th Street, 14FL
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10016
City Area Code	212
Local Phone Number	546-4000
Entity Central Index Key	0000014272
Entity Tax Identification Number	22-0790350
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	2,262,689,755
Document Period End Date	Mar. 31, 2020
Document Transition Report	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Small Business	false
Entity Shell Company	false
Entity Emerging Growth Company	false
Common Stock $0.10 Par Value [Member]
Title of 12(b) Security	Common Stock, $0.10 Par Value
Trading Symbol	BMY
Security Exchange Name	NYSE
1.000% Notes due 2025 [Member]
Title of 12(b) Security	1.000% Notes due 2025
Trading Symbol	BMY25
Security Exchange Name	NYSE
1.750% Notes due 2035 [Member]
Title of 12(b) Security	1.750% Notes due 2035
Trading Symbol	BMY35
Security Exchange Name	NYSE
Bristol Myers Squibb Contingent Value Rights [Member]
Title of 12(b) Security	Bristol-Myers Squibb Contingent Value Rights
Trading Symbol	BMY RT
Security Exchange Name	NYSE
Celgene Contingent Value Rights [Member]
Title of 12(b) Security	Celgene Contingent Value Rights
Trading Symbol	CELG RT
Security Exchange Name	NYSE

CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED) - USD ($)
$ in Millions

3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Revenues

$ 10,781

$ 5,920

Cost of Goods and Services Sold

^[1]

3,662

1,824

Selling, General and Administrative Expense

1,606

1,006

Research and Development Expense

2,372

1,348

Amortization of Acquired Intangible Assets

2,282

24

Other Nonoperating (Income) Expense

1,163

(261)

Costs and Expenses

11,085

3,941

Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest

(304)

1,979

Income Tax Expense (Benefit)

462

264

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

(766)

1,715

Net Income (Loss) Attributable to Noncontrolling Interest

9

5

Net Income (Loss) Attributable to Parent

$ (775)

$ 1,710

Earnings Per Share, Basic

$ (0.34)

$ 1.05

Earnings Per Share, Diluted

$ (0.34)

$ 1.04

Net product sales [Member]

Revenues

$ 10,541

$ 5,713

Alliance and other revenues [Member]

Revenues

$ 240

$ 207

[1]	Excludes amortization of acquired intangible assets

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Statement of Comprehensive Income [Abstract]
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ (766)	$ 1,715
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	70	14
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax	16	49
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax	1	26
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(116)	29
Other Comprehensive Income/(Loss)	(29)	118
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(795)	1,833
Net Income (Loss) Attributable to Noncontrolling Interest	9	5
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$ (804)	$ 1,828

CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 15,817	$ 12,346
Marketable debt securities	2,505	3,047
Receivables	8,290	7,685
Inventories	2,836	4,293
Other current assets	2,405	1,983
Total current assets	31,853	29,354
Property, plant and equipment	6,112	6,252
Goodwill	22,452	22,488
Other intangible assets	61,666	63,969
Deferred income taxes	605	510
Marketable debt securities	651	767
Other non-current assets	5,946	6,604
Total Assets	129,285	129,944
Current Liabilities:
Short-term debt obligations	3,862	3,346
Accounts payable	3,069	2,445
Other current liabilities	12,301	12,513
Total Current Liabilities	19,232	18,304
Accrued Income Taxes, Noncurrent	6,531	6,454
Other non-current liabilities	10,701	10,101
Long-term debt	42,844	43,387
Total Liabilities	79,308	78,246
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock	0	0
Common stock	292	292
Capital in excess of par value of stock	43,254	43,709
Accumulated other comprehensive loss	(1,549)	(1,520)
Retained earnings	32,671	34,474
Less cost of treasury stock	(24,757)	(25,357)
Total Bristol-Myers Squibb Company Shareholders' Equity	49,911	51,598
Stockholders' Equity Attributable to Noncontrolling Interest	66	100
Total Equity	49,977	51,698
Total Liabilities and Equity	$ 129,285	$ 129,944

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash Flows From Operating Activities:
Net Earnings	$ (766)	$ 1,715
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation, Depletion and Amortization	2,477	170
Deferred Income Tax Expense (Benefit)	(53)	78
Share-based Payment Arrangement, Noncash Expense	210	53
Impairment of Long-Lived Assets to be Disposed of	53	45
Pension settlements and amortization	11	66
Divestiture gains and royalties	(173)	(166)
Equity investment, (gain) loss	339	(175)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	556	0
Other Noncash Income (Expense)	(42)	(6)
Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]
Increase (Decrease) in Receivables	(743)	236
Increase (Decrease) in Inventories	1,448	35
Increase (Decrease) in Accounts Payable	703	136
Increase (Decrease) in Income Taxes Payable	229	120
Increase (Decrease) in Other Operating Assets and Liabilities, Net	(355)	(917)
Net Cash Provided by (Used in) Operating Activities	3,894	1,390
Cash Flows From Investing Activities:
Proceeds from Sale and Maturity of Debt Securities, Available-for-sale	1,394	1,211
Payments to Acquire Marketable Debt Securities	(735)	(242)
Payments to Acquire Property, Plant, and Equipment	(186)	(204)
Divestiture and other proceeds	205	310
Payments to Acquire Businesses, Net of Cash Acquired	(25)	(15)
Net Cash Provided by (Used in) Investing Activities	653	1,060
Cash Flows From Financing Activities:
Proceeds from (Repayments of) Short-term Debt	26	(73)
Repayments of Long-term Debt	0	(1,250)
Payments for Repurchase of Common Stock	(81)	0
Payments of Dividends	(1,017)	(669)
Proceeds from (Payments for) Other Financing Activities	18	(37)
Net Cash Provided by (Used in) Financing Activities	(1,054)	(2,029)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(67)	3
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	3,426	424
Cash, Cash Equivalents and Restricted Cash at Beginning of Period	12,820	6,911
Cash, Cash Equivalents and Restricted Cash at End of Period	$ 16,246	$ 7,335

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS (Notes)	3 Months Ended
	Mar. 31, 2020
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS [Abstract]
Basis of Presentation and Recently Issued Accounting Standards [Text Block]	Basis of Consolidation Bristol-Myers Squibb Company prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position at March 31, 2020 and December 31, 2019 and the results of operations and cash flows for the three months ended March 31, 2020 and 2019. All intercompany balances and transactions have been eliminated. BMS's consolidated financial statements include the assets, liabilities, operating results and cash flows of Celgene from the date of acquisition on November 20, 2019. These financial statements and the related notes should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2019 included in the 2019 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document. Business Segment Information BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Consistent with BMS's operational structure, the Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources at the global corporate level. Managing and allocating resources at the global corporate level enables the CEO to assess both the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or franchise basis. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods. For further information on product and regional revenue, see “—Note 2. Revenue.” Use of Estimates and Judgments Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining accounting for business combinations; impairments of intangible assets; sales rebate and return accruals; legal contingencies; and income taxes. Actual results may differ from estimates. Reclassifications Certain reclassifications were made to conform the prior period interim consolidated financial statements to the current period presentation. Recently Adopted Accounting Standards Financial Instruments - Measurement of Credit Losses In June 2016, the FASB issued amended guidance for the measurement of credit losses on financial instruments. Entities will be required to use a forward-looking estimated loss model. Available-for-sale debt security credit losses will be recognized as allowances rather than a reduction in amortized cost. BMS adopted the amended guidance on a modified retrospective approach on January 1, 2020. The amended guidance did not impact BMS’s results of operations.

REVENUE RECOGNITION Revenue Recognition (Notes)

3 Months Ended

Mar. 31, 2020

Revenue Recognition [Abstract]

Revenue from Contract with Customer [Text Block]

REVENUE

The following table summarizes the disaggregation of revenue by nature:



	Three Months Ended March 31,
Dollars in Millions	2020		2019
Net product sales	$	10,541	$	5,713
Alliance revenues	105		129
Other revenues	135		78
Total Revenues	$	10,781	$	5,920

The following table summarizes GTN adjustments:



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Gross product sales	$	14,686		$	7,994
GTN adjustments^(a)
Charge-backs and cash discounts	(1,340		)	(774		)
Medicaid and Medicare rebates	(1,498		)	(800		)
Other rebates, returns, discounts and adjustments	(1,307		)	(707		)
Total GTN adjustments	(4,145		)	(2,281		)
Net product sales	$	10,541		$	5,713


(a)	Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $72 million and $78 million for the three months ended March 31, 2020 and 2019, respectively.

The following table summarizes the disaggregation of revenue by product and region:



	Three Months Ended March 31,
Dollars in Millions	2020		2019
Prioritized Brands
Revlimid	$	2,915	$	—
Eliquis	2,641		1,925
Opdivo	1,766		1,801
Orencia	714		640
Pomalyst/Imnovid	713		—
Sprycel	521		459
Yervoy	396		384
Abraxane	300		—
Empliciti	97		83
Reblozyl	8		—
Inrebic	12		—

Established Brands
Baraclude	122		141
Vidaza	158		—
Other Brands^(a)	418		487
Total Revenues	$	10,781	$	5,920

United States	$	6,766	$	3,449
Europe	2,567		1,480
Rest of the World	1,335		874
Other^(b)	113		117
Total Revenues	$	10,781	$	5,920


(a)	Includes BMS and Celgene products in 2020.


(b)	Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations.

Revenue recognized from performance obligations satisfied in prior periods was $130 million and $147 million for the three months ended March 31, 2020 and 2019, respectively, consisting primarily of royalties for out-licensing arrangements and revised estimates for GTN adjustments related to prior period sales. Contract assets were not material at March 31, 2020 and December 31, 2019.

ALLIANCES

3 Months Ended

Mar. 31, 2020

ALLIANCES [Abstract]

Collaborative Arrangement Disclosure [Text Block]

ALLIANCES

BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and exposed to significant risks and rewards depending on the commercial success of the activities. BMS may either in-license intellectual property owned by the other party or out-license its intellectual property to the other party. These arrangements also typically include research, development, manufacturing, and/or commercial activities and can cover a single investigational compound or commercial product or multiple compounds and/or products in various life cycle stages. The rights and obligations of the parties can be global or limited to geographic regions. BMS refers to these collaborations as alliances and its partners as alliance partners.

Selected financial information pertaining to alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Revenues from alliances:
Net product sales	$	2,723		$	2,378
Alliance revenues	105			129
Total Revenues	$	2,828		$	2,507

Payments to/(from) alliance partners:
Cost of products sold	$	1,306		$	1,019
Marketing, selling and administrative	(40		)	(28		)
Research and development	46			14
Other expense/(income), net	(15		)	(14		)



Dollars in Millions	March 31, 2020		December 31, 2019
Selected Alliance Balance Sheet information:
Receivables – from alliance partners	$	309	$	347
Accounts payable – to alliance partners	1,284		1,026
Deferred income from alliances^(a)	432		431


(a)	Includes unamortized upfront and milestone payments.

The nature, purpose, significant rights and obligations of the parties and specific accounting policy elections for each of the Company's significant alliances are discussed in the 2019 Form 10-K. Significant developments and updates related to alliances during the three months ended March 31, 2020 are set forth below.

Otsuka

Otsuka is no longer co-promoting Sprycel in the U.S. and the EU in 2020 and as a result, this arrangement is no longer considered a collaboration under ASC 808. Revenues earned and fees paid to Otsuka in the Oncology Territory in 2020 are not included in the table above.

ACQUISITIONS, DIVESTITURES AND OTHER ARRANGEMENTS (Notes)

3 Months Ended

Mar. 31, 2020

Acquisitions, Divestitures and Other Arrangements [Abstract]

Mergers, Acquisitions and Dispositions Disclosures [Text Block]

ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS

Acquisitions

Business Combination

Celgene

On November 20, 2019, BMS completed the Celgene acquisition. The acquisition is expected to further position BMS as a leading biopharmaceutical company for sustained innovation and long-term growth and to address the needs of patients with cancer, inflammatory, immunologic or cardiovascular diseases through high-value innovative medicines and leading scientific capabilities. The transaction was accounted for as a business combination, which requires that assets acquired and liabilities assumed be recognized at their fair value as of the acquisition date. The purchase price allocation is preliminary and subject to change, including the valuation of inventory, property, plant and equipment, intangible assets, income taxes and legal contingencies among other items. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. Measurement period adjustments increased goodwill by $22 million in the first quarter of 2020 due to purchase price allocation increases of $58 million to equity investments and $30 million to legal contingency liabilities, net of deferred income taxes.

Divestitures

The following table summarizes the financial impact of divestitures including royalties, which are included in Other expense/(income), net. Revenue and pretax earnings related to all divestitures and assets held-for-sale were not material in all periods presented (excluding divestiture gains or losses).



	Three Months Ended March 31,
	Net Proceeds^(a)				Divestiture Gains					Royalty Income
Dollars in Millions	2020		2019		2020			2019		2020			2019
Diabetes Business	$	153	$	164	$	—		$	—	$	(127	)	$	(165	)
Erbitux*	4		5		—			—		—			—
Manufacturing Operations	—		2		(1		)	—		—			—
Plavix* and Avapro/Avalide	7		—		(12		)	—		—			—
Mature Brands and Other	31		—		(3		)	—		(31		)	(1		)
Total	$	195	$	171	$	(16	)	$	—	$	(158	)	$	(166	)

(a)

Includes royalties received subsequent to the related sale of the asset or business.

OTHER EXPENSE (INCOME), NET

3 Months Ended

Mar. 31, 2020

Other Nonoperating Income (Expense) [Abstract]

Other (Income)/Expense [Text Block]

OTHER EXPENSE/(INCOME), NET



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Interest expense	$	362		$	45
Pension and postretirement	(4		)	44
Royalties and licensing income	(410		)	(308		)
Divestiture gains	(16		)	—
Acquisition expenses	—			165
Contingent consideration	556			—
Investment income	(61		)	(56		)
Integration expenses	174			22
Provision for restructuring	160			12
Equity investment losses/(gains)	339			(175		)
Litigation and other settlements	32			1
Transition and other service fees	(61		)	(2		)
Reversion excise tax	76			—
Other	16			(9		)
Other expense/(income), net	$	1,163		$	(261	)

RESTRUCTURING

3 Months Ended

Mar. 31, 2020

Restructuring Charges [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

RESTRUCTURING

A restructuring and integration plan is being implemented as an initiative to realize $2.5 billion of sustainable run-rate synergies resulting from cost savings and avoidance from the Celgene acquisition. The synergies are expected to be realized in Cost of products sold (10%), Marketing, selling and administrative expenses (55%) and Research and development expenses (35%). The majority of charges are expected to be incurred through 2022, and range between $2.8 billion to $3.0 billion. Cumulative charges of approximately $1.0 billion have been recognized including integration planning and execution expenses, employee termination benefit costs and accelerated stock-based compensation, contract termination costs and other shutdown costs associated with site exits. Cash outlays in connection with these actions are expected to be approximately $2.5 billion. Employee workforce reductions were approximately 600 for the three months ended March 31, 2020.

The following tables summarize the charges and activity related to the Celgene acquisition:



Dollars in Millions	Three Months Ended March 31, 2020
Employee termination costs	$	146
Other termination costs	4
Provision for restructuring	150
Integration expenses	174
Total charges^(a)	$	324


(a)	Included in Other expense/(income), net.



Dollars in Millions	Three Months Ended March 31, 2020
Liability at January 1	$	77
Charges	131
Change in estimates	1
Provision for restructuring^(a)	132
Foreign currency translation and other	6
Payments	(91		)
Liability at March 31	$	124


(a)	Excludes $18 million of accelerated stock-based compensation.

In October 2016, a restructuring plan was announced to evolve and streamline BMS's operating model. The majority of charges are expected to be incurred through 2020, range between $1.6 billion to $2.0 billion. Cumulative charges of approximately $1.5 billion have been recognized including employee termination benefit costs, contract termination costs, accelerated depreciation and impairment charges and other costs associated with manufacturing and R&D site exits. The remaining charges are expected to result from additional site exit costs. Cash outlays in connection with these actions are expected to be approximately 40% to 50% of the total charges.

The following tables summarize the charges and activity related to the Company transformation:



	Three Months Ended March 31,
Dollars in Millions	2020		2019
Employee termination costs	$	3	$	4
Other termination costs	7		8
Provision for restructuring	10		12
Accelerated depreciation	30		31
Asset impairments	42		1
Total charges	$	82	$	44



	Three Months Ended March 31,
Dollars in Millions	2020		2019
Cost of products sold	$	16	$	12
Marketing, selling and administrative	—		1
Research and development	56		19
Other expense/(income), net	10		12
Total charges	$	82	$	44



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Liability at December 31	$	23		$	99
Cease-use liability reclassification	—			(3		)
Liability at January 1	23			96
Charges	7			15
Change in estimates	3			(3		)
Provision for restructuring	10			12
Payments	(16		)	(45		)
Liability at March 31	$	17		$	63

INCOME TAXES

3 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

INCOME TAXES



	Three Months Ended March 31,
Dollars in Millions	2020			2019
(Loss)/Earnings Before Income Taxes	$	(304	)	$	1,979
Provision for Income Taxes	462			264
Effective Tax Rate	(152.0		)%	13.3		%

The tax impact attributed to specified items was primarily due to non-deductible contingent value rights charges, valuation allowance on equity investment fair value adjustments and low jurisdictional tax rates attributed to inventory and intangible asset purchase price adjustments in the three months ended March 31, 2020. The tax impact of these discrete items are reflected immediately and are not considered in estimating the annual effective tax rate. Additional changes to the effective tax rate may occur in future periods due to various reasons including pretax earnings mix, tax reserves, cash repatriations and revised interpretations of the relevant tax code.

BMS is currently under examination by a number of tax authorities, which have proposed or are considering proposing material adjustments to tax positions for issues such as transfer pricing, certain tax credits and the deductibility of certain expenses. It is reasonably possible that new issues will be raised by tax authorities, which may require adjustments to the amount of unrecognized tax benefits; however, an estimate of such adjustments cannot reasonably be made at this time.

It is also reasonably possible that the total amount of unrecognized tax benefits at March 31, 2020 could decrease in the range of approximately $290 million to $330 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benefits may result in the payment of additional taxes, adjustment of certain deferred taxes and/or recognition of tax benefits. It is reasonably possible that new issues will be raised by tax authorities that may increase unrecognized tax benefits; however, an estimate of such increases cannot reasonably be made at this time. BMS believes that it has adequately provided for all open tax years by tax jurisdiction.

EARNINGS PER SHARE

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

(LOSS)/EARNINGS PER SHARE



	Three Months Ended March 31,
Amounts in Millions, Except Per Share Data	2020			2019
Net (Loss)/Earnings Attributable to BMS Used for Basic and Diluted EPS Calculation	$	(775	)	$	1,710

Weighted-Average Common Shares Outstanding – Basic	2,258			1,634
Incremental Shares Attributable to Share-Based Compensation Plans	—			3
Weighted-Average Common Shares Outstanding – Diluted	2,258			1,637

(Loss)/Earnings per Common Share
Basic	$	(0.34	)	$	1.05
Diluted	(0.34		)	1.04

The total number of potential shares of common stock excluded from the diluted EPS computation because of the antidilutive impact was 138 million for the three months ended March 31, 2020.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

Financial assets and liabilities measured at fair value on a recurring basis are summarized below:



	March 31, 2020							December 31, 2019
Dollars in Millions	Level 1		Level 2			Level 3		Level 1		Level 2			Level 3
Cash and cash equivalents - money market and other securities	$	—	$	13,528		$	—	$	—	$	10,448		$	—
Marketable debt securities:
Certificates of deposit	—		1,062			—		—		1,227			—
Commercial paper	—		869			—		—		1,093			—
Corporate debt securities	—		1,225			—		—		1,494			—
Derivative assets			202					—		140			—
Equity investments	1,822		145			—		2,020		175			—
Derivative liabilities	—		(29		)	—		—		(40		)	—
Contingent consideration liability:
Contingent value rights	2,862		—			—		2,275		—			—
Other acquisition related contingent consideration	—		—			69		—		—			106

As further described in “Item 8. Financial Statements and Supplementary Data—Note 9. Financial Instruments and Fair Value Measurements” in the Company's 2019 Form 10-K, the Company's fair value estimates use inputs that are either (1) quoted prices for identical assets or liabilities in active markets (Level 1 inputs); (2) observable prices for similar assets or liabilities in active markets or for identical or similar assets or liabilities in markets that are not active (Level 2 inputs); or (3) unobservable inputs (Level 3 inputs).

Contingent consideration obligations are recorded at their estimated fair values and these obligations are revalued each reporting period until the related contingencies are resolved. The contingent value rights are adjusted to fair value using the traded price of the securities at the end of each reporting period. The fair value measurements for other contingent consideration liabilities are estimated using probability-weighted discounted cash flow approaches that are based on significant unobservable inputs related to product candidates acquired in business combinations and are reviewed quarterly. These inputs include, as applicable, estimated probabilities and timing of achieving specified development and regulatory milestones, estimated annual sales and the discount rate used to calculate the present value of estimated future payments. Significant changes which increase or decrease the probabilities of achieving the related development and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of these obligations. The fair value of our contingent consideration as of March 31, 2020 was calculated using the following significant unobservable inputs:



	Ranges (weighted average) utilized as of:
Inputs	March 31, 2020
Discount rate	2.2% to 2.7% (2.4%)
Probability of payment	0% to 80% (2.6%)
Projected year of payment for development and regulatory milestones	2020 to 2029 (2022)
Projected year of payment for sales-based milestones and other amounts calculated as a percentage of annual sales	N/A

There were no transfers between levels 1, 2 and 3 during the three months ended March 31, 2020. The following table represents a roll-forward of the fair value of level 3 instruments:



Dollars in Millions	Three Months Ended March 31, 2020
Fair value as of January 1	$	106
Changes in estimated fair value	(36		)
Foreign exchange	(1		)
Fair value as of March 31	$	69

Available-for-sale Debt Securities and Equity Investments

Changes in fair value of equity investments are included in Other expense/(income), net. The following table summarizes available-for-sale debt securities and equity investments:



	March 31, 2020									December 31, 2019
Dollars in Millions	Amortized Cost		Gross Unrealized							Amortized Cost		Gross Unrealized
Dollars in Millions	Amortized Cost		Gains		Losses			Fair Value		Amortized Cost		Gains		Losses			Fair Value
Certificates of deposit	$	1,062	$	—	$	—		$	1,062	$	1,227	$	—	$	—		$	1,227
Commercial paper	869		—		—			869		1,093		—		—			1,093
Corporate debt securities	1,216		11		(2		)	1,225		1,487		8		(1		)	1,494
	$	3,147	$	11	$	(2	)	3,156		$	3,807	$	8	$	(1	)	3,814

Equity investments								1,967									2,195
Total								$	5,123								$	6,009



Dollars in Millions	March 31, 2020		December 31, 2019
Marketable debt securities - current	$	2,505	$	3,047
Marketable debt securities - non-current^(a)	651		767
Other non-current assets	1,967		2,195
Total	$	5,123	$	6,009


(a)	All non-current marketable debt securities mature within five years as of March 31, 2020 and December 31, 2019.

Equity investments not measured at fair value and excluded from the above fair value table were limited partnerships and other equity method investments of $424 million at March 31, 2020 and $429 million at December 31, 2019 and other equity investments without readily determinable fair values of $754 million at March 31, 2020 and $781 million at December 31, 2019. These amounts are included in Other non-current assets. Upward adjustments to equity investments without readily determinable fair values for the three months ended March 31, 2020 were $75 million resulting from observable price changes for similar securities for the same issuer and were recorded in Other expense/(income), net. Downward adjustments to equity investments without readily determinable fair values for the three months ended March 31, 2020 were $188 million due to the significant adverse change in the global economy during the period primarily caused by the COVID-19 pandemic.

The following table summarizes the net (loss)/gain recorded for equity investments with readily determinable fair values held as of March 31, 2020 and 2019:



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Net (loss)/gain recognized	$	(228	)	$	95
Less: Net gain recognized for equity investments sold	—			14
Net unrealized (loss)/gain on equity investments held	$	(228	)	$	81

Qualifying Hedges and Non-Qualifying Derivatives

Cash Flow Hedges — Foreign currency forward contracts are used to hedge certain forecasted intercompany inventory purchases and sales transactions and certain foreign currency transactions. The fair value for contracts designated as cash flow hedges are temporarily reported in Accumulated other comprehensive loss and included in earnings when the hedged item affects earnings. The net gain or loss on foreign currency forward contracts is expected to be reclassified to net earnings (primarily included in Cost of products sold and Other expense/(income), net) within the next 12 months. The notional amount of outstanding foreign currency forward contracts was primarily attributed to the euro of $1.7 billion and Japanese yen of $1.2 billion at March 31, 2020.

The earnings impact related to discontinued cash flow hedges and hedge ineffectiveness was not material during all periods presented. Cash flow hedge accounting is discontinued when the forecasted transaction is no longer probable of occurring within 60 days after the originally forecasted date or when the hedge is no longer effective. Assessments to determine whether derivatives designated as qualifying hedges are highly effective in offsetting changes in the cash flows of hedged items are performed at inception and on a quarterly basis. Foreign currency forward contracts not designated as hedging instruments are used to offset exposures in certain foreign currency denominated assets, liabilities and earnings. Changes in the fair value of these derivatives are recognized in earnings as they occur.

BMS may hedge a portion of its future foreign currency exposure by utilizing a strategy that involves both a purchased local currency put option and a written local currency call option that are accounted for as hedges of future sales denominated in that local currency. Specifically, BMS sells (or writes) a local currency call option and purchases a local currency put option with the same expiration dates and local currency notional amounts but with different strike prices. The premium collected from the sale of the call option is equal to the premium paid for the purchased put option, resulting in no net premium being paid. This combination of transactions is generally referred to as a “zero-cost collar.” The expiration dates and notional amounts correspond to the amount and timing of forecasted foreign currency sales. The foreign currency zero-cost collar contracts outstanding as of March 31, 2020 had settlement dates within 12 months. If the U.S. Dollar weakens relative to the currency of the hedged anticipated sales, the purchased put option value reduces to zero and we benefit from the increase in the U.S. Dollar equivalent value of our anticipated foreign currency cash flows; however, this benefit would be capped at the strike level of the written call, which forms the upper end of the collar.

Net Investment Hedges — Non-U.S. dollar borrowings of €950 million ($1.0 billion) at March 31, 2020 are designated as net investment hedges to hedge euro currency exposures of the net investment in certain foreign affiliates and are recognized in long-term debt. The effective portion of foreign exchange gain on the remeasurement of euro debt was included in the foreign currency translation component of Accumulated other comprehensive loss with the related offset in long-term debt. Contract fair value changes are recorded in the foreign currency translation component of Other Comprehensive (Loss)/Income with a related offset in Other non-current assets or Other non-current liabilities.

Cross-currency interest rate swap contracts of $400 million at March 31, 2020 are designated to hedge Japanese yen currency exposure of BMS's net investment in its Japan subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of Other Comprehensive (Loss)/Income with a related offset in Other non-current assets or Other non-current liabilities.

Fair Value Hedges — Fixed to floating interest rate swap contracts are designated as fair value hedges and used as an interest rate risk management strategy to create an appropriate balance of fixed and floating rate debt. The contracts and underlying debt for the hedged benchmark risk are recorded at fair value. The effective interest rate for the contracts is one-month LIBOR (1.0% as of March 31, 2020) plus an interest rate spread of 4.6%. Gains or losses resulting from changes in fair value of the underlying debt attributable to the hedged benchmark interest rate risk are recorded in interest expense with an associated offset to the carrying value of debt. Since the specific terms and notional amount of the swap are intended to align with the debt being hedged, all changes in fair value of the swap are recorded in interest expense with an associated offset to the derivative asset or liability on the consolidated balance sheet. As a result, there was no net impact in earnings. When the underlying swap is terminated prior to maturity, the fair value adjustment to the underlying debt is amortized as a reduction to interest expense over the remaining term of the debt.

The following table summarizes the fair value of outstanding derivatives:



	March 31, 2020									December 31, 2019
	Asset^(a)				Liability^(b)					Asset^(a)				Liability^(b)
Dollars in Millions	Notional		Fair Value		Notional		Fair Value			Notional		Fair Value		Notional		Fair Value
Derivatives designated as hedging instruments:
Interest rate swap contracts	$	255	$	25	$	—	$	—		$	255	$	6	$	—	$	—
Cross-currency interest rate swap contracts	400		7		—		—			175		2		125		(1		)
Foreign currency forward contracts	2,383		75		301		(2		)	766		27		980		(20		)

Derivatives not designated as hedging instruments:
Foreign currency forward contracts	1,177		73		772		(19		)	2,342		91		1,173		(10		)
Foreign currency zero-cost collar contracts	1,522		22		1,597		(8		)	2,482		14		2,235		(9		)


(a)	Included in Other current assets and Other non-current assets.


(b)	Included in Other current liabilities and Other non-current liabilities.

The following table summarizes the financial statement classification and amount of (gain)/loss recognized on hedging instruments:



	Three Months Ended March 31, 2020
Dollars in Millions	Cost of products sold			Other expense/(income), net
Interest rate swap contracts	$	—		$	(7	)
Cross-currency interest rate swap contracts	—			(2		)
Foreign currency forward contracts	(23		)	(76		)
Foreign currency zero-cost collar contracts	—			(9		)



	Three Months Ended March 31, 2019
Dollars in Millions	Cost of products sold			Other expense/(income), net
Interest rate swap contracts	$	—		$	(5	)
Cross-currency interest rate swap contracts	—			(2		)
Foreign currency forward contracts	(30		)	9
Forward starting interest rate swap options	—			35

The following table summarizes the effect of derivative and non-derivative instruments designated as hedging instruments in Other Comprehensive (Loss)/Income:



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Derivatives qualifying as cash flow hedges
Foreign currency forward contracts gain/(loss):
Recognized in Other Comprehensive (Loss)/Income^(a)	$	97		$	45
Reclassified to Cost of products sold	(20		)	(30		)

Derivatives qualifying as net investment hedges
Cross-currency interest rate swap contracts gain:
Recognized in Other Comprehensive (Loss)/Income	6			6

Non-derivatives qualifying as net investment hedges
Non-U.S. dollar borrowings gain:
Recognized in Other Comprehensive (Loss)/Income	20			8


(a)	The amount is expected to be reclassified into earnings in the next 12 months.

Debt Obligations

Short-term debt obligations include:



Dollars in Millions	March 31, 2020		December 31, 2019
Non-U.S. short-term borrowings	$	345	$	351
Current portion of long-term debt	3,261		2,763
Other	256		232
Total	$	3,862	$	3,346

Long-term debt and the current portion of long-term debt include:



Dollars in Millions	March 31, 2020			December 31, 2019
Principal Value	$	44,310		$	44,335

Adjustments to Principal Value:
Fair value of interest rate swap contracts	25			6
Unamortized basis adjustment from swap terminations	168			175
Unamortized bond discounts and issuance costs	(271		)	(280		)
Unamortized purchase price adjustments of Celgene debt	1,873			1,914
Total	$	46,105		$	46,150

Current portion of long-term debt	$	3,261		$	2,763
Long-term debt	42,844			43,387
Total	$	46,105		$	46,150

The fair value of long-term debt was $51.9 billion at March 31, 2020 and $50.7 billion at December 31, 2019 valued using Level 2 inputs, which are based upon the quoted market prices for the same or similar debt instruments. The fair value of short-term borrowings approximates the carrying value due to the short maturities of the debt instruments. Interest payments were $491 million and $57 million for the three months ended March 31, 2020 and 2019, respectively, net of amounts related to interest rate swap contracts.

During the first quarter of 2019, the $750 million 1.600% Notes and the $500 million 1.750% Notes matured and were repaid.

As of March 31, 2020, BMS had four separate revolving credit facilities totaling $6.0 billion, which consisted of a 364-day $2.0 billion facility expiring in January 2021, a $1.0 billion facility that was renewed to January 2022 and two five-year $1.5 billion facilities that were extended to September 2023 and July 2024, respectively. The facilities provide for customary terms and conditions with no financial covenants and may be used to provide backup liquidity for BMS's commercial paper borrowings. BMS's $1.0 billion facility and its two $1.5 billion revolving facilities are extendable annually by one year on the anniversary date with the consent of the lenders. BMS's 364-day $2.0 billion facility can be renewed for one year on each anniversary date, subject to certain terms and conditions. No borrowings were outstanding under revolving credit facilities at March 31, 2020 or December 31, 2019.

RECEIVABLES

3 Months Ended

Mar. 31, 2020

Accounts Receivable, after Allowance for Credit Loss [Abstract]

Receivables [Text Block]

RECEIVABLES



Dollars in Millions	March 31, 2020			December 31, 2019
Trade receivables	$	7,660		$	6,888
Less charge-backs and cash discounts	(437		)	(391		)
Less bad debt allowances	(23		)	(21		)
Net trade receivables	7,200			6,476
Alliance, royalties, VAT and other	1,090			1,209
Receivables	$	8,290		$	7,685

Non-U.S. receivables sold on a nonrecourse basis were $180 million and $174 million for the three months ended March 31, 2020 and 2019, respectively. Receivables from the three largest customers in the U.S. represented approximately 55% and 50% of total trade receivables at March 31, 2020 and December 31, 2019, respectively.

INVENTORIES

3 Months Ended

Mar. 31, 2020

Inventory, Net [Abstract]

Inventories [Text Block]

INVENTORIES



Dollars in Millions	March 31, 2020		December 31, 2019
Finished goods	$	1,283	$	2,227
Work in process	2,651		3,267
Raw and packaging materials	164		172
Total inventories	$	4,098	$	5,666

Inventories	$	2,836	$	4,293
Other non-current assets	1,262		1,373

Total inventories include fair value adjustments resulting from the Celgene acquisition of $2.1 billion at March 31, 2020 and $3.5 billion at December 31, 2019. Other non-current assets include inventory expected to remain on hand beyond one year in both periods.

PROPERTY, PLANT AND EQUIPMENT

3 Months Ended

Mar. 31, 2020

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Text Block]

PROPERTY, PLANT AND EQUIPMENT



Dollars in Millions	March 31, 2020			December 31, 2019
Land	$	194		$	187
Buildings	5,848			6,336
Machinery, equipment and fixtures	3,055			3,157
Construction in progress	456			527
Gross property, plant and equipment	9,553			10,207
Less accumulated depreciation	(3,441		)	(3,955		)
Property, plant and equipment	$	6,112		$	6,252

Depreciation expense was $170 million and $133 million for the three months ended March 31, 2020 and 2019, respectively.

GOODWILL AND OTHER INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets Disclosure [Text Block]

GOODWILL AND OTHER INTANGIBLE ASSETS



Dollars in Millions	Estimated Useful Lives	March 31, 2020			December 31, 2019
Goodwill^(a)		$	22,452		$	22,488

Other intangible assets:
Licenses	5 – 15 years	482			482
Acquired developed product rights	3 – 15 years	50,427			46,827
Capitalized software	3 – 10 years	1,263			1,297
IPRD		15,900			19,500
Gross other intangible assets		68,072			68,106
Less accumulated amortization		(6,406		)	(4,137		)
Other intangible assets		$	61,666		$	63,969


(a)	Includes measurement period adjustments. Refer to “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for more information.

In March 2020, $3.6 billion of IPRD was reclassified to acquired developed product rights upon approval of Zeposia in the U.S. In April 2020, the FDA approved Reblozyl to treat Anemia in adults with lower-risk MDS. As a result, $7.5 billion of IPRD will be reclassed to acquired developed products rights in the second quarter of 2020. Amortization expense of other intangible assets was $2.3 billion and $53 million for the three months ended March 31, 2020 and 2019, respectively.

SUPPLEMENTAL FINANCIAL INFORMATION

3 Months Ended

Mar. 31, 2020

Supplemental Financial Information [Abstract]

Additional Financial Information Disclosure [Text Block]

SUPPLEMENTAL FINANCIAL INFORMATION



Dollars in Millions	March 31, 2020		December 31, 2019
Prepaid and refundable income taxes	$	999	$	754
Research and development	445		410
Other	961		819
Other current assets	$	2,405	$	1,983



Dollars in Millions	March 31, 2020		December 31, 2019
Equity investments	$	3,144	$	3,405
Inventories	1,262		1,373
Operating leases	724		704
Pension and postretirement	189		456
Restricted cash^(a)	342		390
Other	285		276
Other non-current assets	$	5,946	$	6,604


(a)	Restricted cash consists of escrow for litigation settlements and funds restricted for annual Company contributions to the defined contribution plan in the U.S. Restricted cash of $429 million was included in cash, cash equivalents and restricted cash at March 31, 2020 in the consolidated statements of cash flows.



Dollars in Millions	March 31, 2020		December 31, 2019
Rebates and returns	$	4,407	$	4,275
Income taxes payable	1,996		1,517
Employee compensation and benefits	678		1,457
Research and development	1,308		1,324
Dividends	1,037		1,025
Interest	393		493
Royalties	328		418
Operating leases	136		133
Other	2,018		1,871
Other current liabilities	$	12,301	$	12,513



Dollars in Millions	March 31, 2020		December 31, 2019
Income taxes payable	$	5,364	$	5,368
Contingent value rights	2,862		2,275
Pension and postretirement	841		725
Operating leases	688		672
Deferred income	394		424
Deferred compensation	254		287
Other	298		350
Other non-current liabilities	$	10,701	$	10,101

EQUITY

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

EQUITY

The following table summarizes changes in equity for the three months ended March 31, 2020:



	Common Stock			Capital in Excess of Par Value of Stock			Accumulated Other Comprehensive Loss			Retained Earnings			Treasury Stock					Noncontrolling Interest
Dollars and Shares in Millions	Shares	Par Value		Capital in Excess of Par Value of Stock			Accumulated Other Comprehensive Loss			Retained Earnings			Shares		Cost			Noncontrolling Interest
Balance at December 31, 2019	2,923	$	292	$	43,709		$	(1,520	)	$	34,474		672		$	(25,357	)	$	100
Net loss	—	—		—			—			(775		)	—		—			9
Other Comprehensive Loss	—	—		—			(29		)	—			—		—			—
Cash dividends declared^(a)	—	—		—			—			(1,028		)	—		—			—
Share repurchase program	—	—		—			—			—			1		(81		)	—
Stock compensation	—	—		(455		)	—			—			(13	)	681			—
Distributions	—	—		—			—			—			—		—			(43		)
Balance at March 31, 2020	2,923	$	292	$	43,254		$	(1,549	)	$	32,671		660		$	(24,757	)	$	66


(a)	Cash dividends declared per common share were $0.45 for the three months ended March 31, 2020.

The following table summarizes changes in equity for the three months ended March 31, 2019:



	Common Stock			Capital in Excess of Par Value of Stock		Accumulated Other Comprehensive Loss			Retained Earnings			Treasury Stock					Noncontrolling Interest
Dollars and Shares in Millions	Shares	Par Value		Capital in Excess of Par Value of Stock		Accumulated Other Comprehensive Loss			Retained Earnings			Shares		Cost			Noncontrolling Interest
Balance at December 31, 2018	2,208	$	221	$	2,081	$	(2,762	)	$	34,065		576		$	(19,574	)	$	96
Accounting change - cumulative effect^(a)	—	—		—		—			5			—		—			—
Adjusted balance at January 1, 2019	2,208	221		2,081		(2,762		)	34,070			576		(19,574		)	96
Net earnings	—	—		—		—			1,710			—		—			5
Other Comprehensive Income	—	—		—		118			—			—		—			—
Cash dividends declared^(b)	—	—		—		—			(671		)	—		—			—
Stock compensation	—	—		22		—			—			(4	)	3			—
Distributions	—	—		—		—			—			—		—			(2		)
Balance at March 31, 2019	2,208	$	221	$	2,103	$	(2,644	)	$	35,109		572		$	(19,571	)	$	99


(a)	Refer to “—Note 1. Accounting Policies and Recently Issued Accounting Standards” in the Company's 2019 Form 10-K for additional information.


(b)	Cash dividends declared per common share were $0.41 for the three months ended March 31, 2019.

BMS has a share repurchase program, authorized by its Board of Directors, allowing for repurchases of its shares. Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized utilizing the first-in first-out method.

The outstanding share repurchase authority authorization under the program was $1.0 billion as of December 31, 2019. In February 2020, the Board of Directors approved an increase of $5.0 billion to the share repurchase authorization for BMS's common stock. BMS repurchased 1.4 million shares of its common stock for $81 million in the first quarter of 2020. The remaining share repurchase capacity under the share repurchase program was approximately $5.9 billion as of March 31, 2020.

The components of Other Comprehensive (Loss)/Income were as follows:



	2020									2019
Dollars in Millions	Pretax			Tax			After Tax			Pretax			Tax			After Tax
Three Months Ended March 31,
Derivatives qualifying as cash flow hedges:
Unrealized gains/(losses)	$	97		$	(10	)	$	87		$	45		$	(5	)	$	40
Reclassified to net earnings^(a)	(20		)	3			(17		)	(30		)	4			(26		)
Derivatives qualifying as cash flow hedges	77			(7		)	70			15			(1		)	14

Pension and postretirement benefits:
Actuarial gains/(losses)	8			(2		)	6			(2		)	—			(2		)
Amortization^(b)	9			(1		)	8			17			(4		)	13
Settlements^(b)	2			—			2			49			(11		)	38
Pension and postretirement benefits	19			(3		)	16			64			(15		)	49

Available-for-sale debt securities:
Unrealized gains	2			(1		)	1			23			—			23
Realized losses	—			—			—			3			—			3
Available-for-sale debt securities	2			(1		)	1			26			—			26

Foreign currency translation	(110		)	(6		)	(116		)	32			(3		)	29

Other Comprehensive (Loss)/Income	$	(12	)	$	(17	)	$	(29	)	$	137		$	(19	)	$	118


(a)	Included in Cost of products sold.


(b)	Included in Other expense/(income), net.

The accumulated balances related to each component of Other Comprehensive (Loss)/Income, net of taxes, were as follows:



Dollars in Millions	March 31, 2020			December 31, 2019
Derivatives qualifying as cash flow hedges	$	89		$	19
Pension and postretirement benefits	(883		)	(899		)
Available-for-sale debt securities	7			6
Foreign currency translation	(762		)	(646		)
Accumulated other comprehensive loss	$	(1,549	)	$	(1,520	)

PENSION AND POSTRETIREMENT BENEFIT PLANS

3 Months Ended

Mar. 31, 2020

Retirement Benefits [Abstract]

Pension and Other Postretirement Benefits [Text Block]

RETIREMENT BENEFITS

The net periodic benefit cost of defined benefit pension plans includes:



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Service cost – benefits earned during the year	$	12		$	7
Interest cost on projected benefit obligation	8			44
Expected return on plan assets	(23		)	(64		)
Amortization of prior service credits	(1		)	(1		)
Amortization of net actuarial loss	11			18
Curtailments and settlements	2			49
Net periodic pension benefit cost	$	9		$	53

Pension settlement charges were recognized after determining the annual lump sum payments will exceed the annual interest and service costs for certain pension plans. The charges included the acceleration of a portion of unrecognized actuarial losses. Non-current pension liabilities were $560 million at March 31, 2020 and $569 million at December 31, 2019. Defined contribution plan expense in the U.S. was approximately $85 million and $40 million for the three months ended March 31, 2020 and 2019, respectively. Comprehensive medical and group life benefits are provided for substantially all U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The net periodic benefit credits were not material in both periods.

As a result of the Bristol-Myers Squibb Retirement Income Plan termination in 2019, $381 million of assets held in a separate account within the Pension Trust used to fund retiree medical plan payments was reverted back to the Company, resulting in an excise tax of $76 million in the first quarter of 2020.

EMPLOYEE STOCK BENEFIT PLANS Employee Stock Benefit Plans (Notes)

3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement, Disclosure [Abstract]

Share-based Payment Arrangement [Text Block]

EMPLOYEE STOCK BENEFIT PLANS

Stock-based compensation expense was as follows:



	Three Months Ended March 31,
Dollars in Millions	2020		2019
Cost of products sold	$	10	$	4
Marketing, selling and administrative	88		30
Research and development	94		19
Other expense/(income), net	18		—
Total stock-based compensation expense	$	210	$	53

Income tax benefit^(a)	$	46	$	10


(a)	Income tax benefit excludes excess tax benefits of $23 million and $2 million from share-based compensation awards that were vested or exercised during the three months ended March 31, 2020 and 2019, respectively.

The total stock-based compensation expense for the three months ended March 31, 2020 includes $123 million related to the Celgene post-combination service period for the replacement awards and $18 million of accelerated vesting of the replacement awards related to the Celgene acquisition. It also includes $9 million related to CVR obligation on unvested stock awards.

The number of units granted and the weighted-average fair value on the grant date for the three months ended March 31, 2020 were as follows:



Units in Millions	Units	Weighted-Average Fair Value
Restricted stock units	12.5	$	53.63
Market share units	0.9	53.88
Performance share units	1.4	55.66



Dollars in Millions	Stock Options		Restricted Stock Units		Market Share Units		Performance Share Units
Unrecognized compensation cost	$	92	$	1,397	$	77	$	135
Expected weighted-average period in years of compensation cost to be recognized	1.9		2.9		3.4		2.1

LEGAL PROCEEDINGS AND CONTINGENCIES	3 Months Ended
LEGAL PROCEEDINGS AND CONTINGENCIES	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies [Text Block]	LEGAL PROCEEDINGS AND CONTINGENCIES BMS and certain of its subsidiaries are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that BMS believes could become significant or material are described below. While BMS does not believe that any of these matters, except as otherwise specifically noted below, will have a material adverse effect on its financial position or liquidity as BMS believes it has substantial defenses in the matters, the outcomes of BMS’s legal proceedings and other contingencies are inherently unpredictable and subject to significant uncertainties. There can be no assurance that there will not be an increase in the scope of one or more of these pending matters or any other or future lawsuits, claims, government investigations or other legal proceedings will not be material to BMS’s financial position, results of operations or cash flows for a particular period. Furthermore, failure to enforce BMS’s patent rights would likely result in substantial decreases in the respective product revenues from generic competition. Unless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will be incurred and the amount of the related loss can be reasonably estimated. Developments in legal proceedings and other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. For a discussion of BMS’s tax contingencies, see “—Note 7. Income Taxes”. INTELLECTUAL PROPERTY Anti-PD-1 Antibody Litigation In September 2015, Dana-Farber Cancer Institute (“Dana-Farber”) filed a complaint in the U.S. District Court for the District of Massachusetts seeking to correct the inventorship on up to six related U.S. patents directed to methods of treating cancer using PD-1 and PD-L1 antibodies. Specifically, Dana-Farber is seeking to add two scientists as inventors to these patents. In October 2017, Pfizer was allowed to intervene in this case alleging that one of the scientists identified by Dana-Farber was employed by a company eventually acquired by Pfizer during the relevant period. In February 2019, BMS settled the lawsuit with Pfizer. A bench trial in the lawsuit with Dana-Farber took place in February 2019. In May 2019, the Court issued an opinion ruling that the two scientists should be added as inventors to the patents. The decision was appealed to the Federal Circuit. In June 2019, Dana Farber filed a new lawsuit in the District of Massachusetts against BMS seeking damages as a result of the Court’s decision adding the scientists as inventors. This case has been stayed pending the outcome of BMS’s appeal to the Federal Circuit. CAR T On October 18, 2017, the day on which the FDA approved Kite Pharma, Inc.’s (“Kite”) Yescarta* product, Juno, along with Sloan Kettering Institute for Cancer Research (“SKI”), filed a complaint against Kite in the U.S. District Court for the Central District of California. The complaint alleged that Yescarta* infringes certain claims of U.S. Patent No. 7,446,190 (“the ’190 Patent”) concerning CAR T cell technologies. Kite filed an answer and counterclaims asserting non-infringement and invalidity of the ’190 Patent. In December 2019, following an eight-day trial, the jury rejected Kite’s defenses, finding that Kite willfully infringed the ’190 Patent and awarding to Juno and SKI a reasonable royalty consisting of a $585 million upfront payment and a 27.6% running royalty on Kite’s sales of Yescarta* through the expiration of the ’190 Patent in August 2024. In January 2020, Kite renewed its previous motion for judgment as a matter of law and also moved for a new trial, and Juno filed a motion seeking enhanced damages, supplemental damages, ongoing royalties, and prejudgment interest. In March 2020, the Court denied both of Kite’s motions in their entirety. In April 2020, the Court granted in part Juno’s motion and entered a final judgment awarding to Juno and SKI approximately $1.2 billion in royalties, interest and enhanced damages and a 27.6% running royalty on Kite’s sales of Yescarta* from December 13, 2019 through the expiration of the ’190 Patent in August 2024. In April 2020, Kite appealed the final judgment to the U.S. Court of Appeals for the Federal Circuit. The Appeals Court has not yet entered a schedule for the appeal. Eliquis - U.S. In 2017, BMS received Notice Letters from twenty-five generic companies notifying BMS that they had filed aNDAs containing paragraph IV certifications seeking approval of generic versions of Eliquis. As a result, two Eliquis patents listed in the FDA Orange Book are being challenged: the composition of matter patent claiming apixaban specifically and a formulation patent. In response, BMS, along with its partner Pfizer, initiated patent infringement actions under the Hatch-Waxman Act against all generic filers in the U.S. District Court for the District of Delaware in April 2017. In August 2017, the U.S. Patent and Trademark Office granted patent term restoration to the composition of matter patent, thereby restoring the term of the Eliquis composition of matter patent, which is BMS’s basis for projected LOE, from February 2023 to November 2026. BMS settled with a number of aNDA filers. These settlements do not affect BMS’s projected LOE for Eliquis. A trial with the remaining aNDA filers took place in late 2019. Post-trial briefing is complete and BMS is expecting a decision in 2020. Plavix* - Australia Sanofi was notified that, in August 2007, GenRx Proprietary Limited (“GenRx”) obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc., subsequently changed its name to Apotex (“GenRx-Apotex”). In August 2007, GenRx-Apotex filed an application in the Federal Court of Australia seeking revocation of Sanofi’s Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court of Australia granted Sanofi’s injunction. A subsidiary of BMS was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a revocation suit against the same patent. This case was consolidated with the GenRx-Apotex case. On August 12, 2008, the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. BMS and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia (“Full Court”) appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims. GenRx-Apotex appealed the holding of validity of the clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate claims. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In March 2010, the High Court of Australia denied a request by BMS and Sanofi to hear an appeal of the Full Court decision. The case was remanded to the Federal Court for further proceedings related to damages sought by GenRx-Apotex. BMS and GenRx-Apotex settled, and the GenRx-Apotex case was dismissed. The Australian government intervened in this matter seeking maximum damages up to 449 million AUD ($276 million), plus interest, which would be split between BMS and Sanofi, for alleged losses experienced for paying a higher price for branded Plavix* during the period when the injunction was in place. BMS and Sanofi dispute that the Australian government is entitled to any damages. A trial was concluded in September 2017. In April 2020, the Federal Court issued a decision dismissing the Australian government's claim for damages. The Australian government can appeal the Federal Court’s decision. Pomalyst - U.S. Beginning in 2017, Celgene received Notice letters on behalf of Teva Pharmaceuticals USA, Inc. (“Teva”); Apotex Inc. (“Apotex”) and Apotex Corp.; Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero Drugs Limited, Hetero USA, Inc. (together, “Hetero”); Aurobindo Pharma Ltd.; Mylan Pharmaceuticals Inc.; and Breckenridge Pharmaceutical, Inc. (“Breckenridge”) notifying Celgene that they had filed aNDAs containing paragraph IV certifications seeking approval to market generic versions of Pomalyst in the U.S. In response, Celgene filed patent infringement actions against the companies in the U.S. District Court for the District of New Jersey asserting certain FDA Orange Book-listed patents and the companies filed answers, counterclaims and declaratory judgment actions alleging that the asserted patents are invalid, unenforceable and not infringed. These first set of litigations were subsequently consolidated. In March 2020, Celgene subsequently filed additional patent infringement actions in the U.S. District Court for the District of New Jersey against the companies asserting a newly-issued patent that is listed in the FDA Orange Book and that covers formulations comprising pomalidomide. In April 2020, Breckenridge filed its answer and counterclaims alleging that the patent is invalid and not infringed. The other companies have not yet submitted any responsive pleading. The Court has consolidated these additional litigations with the first set of litigations. A trial is scheduled to begin in September 2020. In February and March 2019, Celgene subsequently filed additional patent infringement actions in the U.S. District Court for the District of New Jersey against the companies asserting certain patents that are not listed in the FDA Orange Book and that cover polymorphic forms of pomalidomide, and the companies filed answer and/or counterclaims alleging that each of these patents is invalid and/or not infringed. In these actions, the Court has ordered that the parties be ready for trial by April 15, 2021. In June 2019, Celgene received a Notice Letter from Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (together, “DRL”) notifying Celgene that they had filed an aNDA containing paragraph IV certifications seeking approval to market a generic version of Pomalyst in the U.S. In response, Celgene initiated a patent infringement action against DRL in the U.S. District Court for the District of New Jersey asserting certain FDA Orange Book-listed patents, and DRL filed an answer and counterclaims alleging that each of the patents is invalid and/or not infringed. The Court has not set a trial date in this action. In March 2020, Celgene filed an additional patent infringement action in the U.S. District Court for the District of New Jersey against DRL asserting a newly-issued patent that is listed in the FDA Orange Book and that covers formulations comprising pomalidomide. DRL has not yet submitted a responsive pleading, and the Court has not set a trial date in this action. Pomalyst - Canada Celgene received a Notice of Allegation in January 2020 from Natco Pharma (Canada) Inc. (“Natco Canada”) notifying Celgene that it had filed an Abbreviated New Drug Submission (“aNDS”) with Canada’s Minister of Health with respect to certain of Celgene’s Canadian patents. Natco Canada is seeking to market a generic version of Pomalyst in Canada. In response, Celgene initiated a patent infringement action in the Federal Court of Canada and sought an injunction. Natco Canada alleges that the asserted patents are invalid and/or not infringed. The Court has set the trial to begin on November 15, 2021. Celgene received a Notice of Allegation in March 2020 from Dr. Reddy’s Laboratories Ltd. (“DRL Canada”) notifying Celgene that it had filed an aNDS with Canada’s Minister of Health with respect to certain of Celgene’s Canadian patents. DRL Canada is seeking to market a generic version of Pomalyst in Canada. In response, Celgene initiated a patent infringement action in the Federal Court of Canada and sought an injunction. DRL Canada alleges that the asserted patents are invalid and/or not infringed. The Court has not set a trial date. Revlimid - Canada Celgene received two Notices of Allegation in July 2018 from Natco Canada notifying Celgene of the filing of Natco Canada’s two separate aNDSs with Canada’s Minister of Health with respect to certain of Celgene’s Canadian patents. Natco Canada is seeking to market a generic version of Revlimid in Canada. In response, Celgene initiated patent infringement actions in the Federal Court of Canada and sought an injunction. Natco alleges that the asserted patents are invalid and/or not infringed. The trial, which was scheduled to start on March 30, 2020, has been postponed due to COVID-19. The Court has not set a new trial date. Revlimid - U.S. Celgene has received Notice Letters on behalf of DRL; Zydus Pharmaceuticals (USA) Inc.; Cipla Ltd., India; Apotex; Sun Pharma Global FZE, Sun Pharma Global Inc., Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited (“Sun”); Hetero; Mylan Pharmaceuticals Inc., Mylan Inc., and Mylan N.V. (“Mylan”); and Aurobindo Pharma Limited, Eugia Pharma Specialities Limited, Aurobindo Pharma USA, Inc., and Aurolife Pharma LLC notifying Celgene that they had filed aNDAs containing paragraph IV certifications seeking approval to market generic versions of Revlimid in the U.S. In response, Celgene filed patent infringement actions against the companies in the U.S. District Court for the District of New Jersey asserting certain FDA Orange Book-listed patents as well as other litigations asserting other non-FDA Orange Book-listed patents against certain defendants, some of which have filed answers and/or counterclaims alleging that the asserted patents are invalid and/or not infringed. In a second litigation involving Sun, Sun filed a motion to dismiss, which was denied. Sun has not yet filed a responsive pleading in that second litigation. Mylan has filed a motion to dismiss the District of New Jersey action, and that motion remains pending. Celgene also filed a patent infringement action against Mylan in the U.S. District Court for the Northern District of West Virginia asserting certain FDA Orange Book-listed patents. In April 2020, Mylan Pharmaceuticals Inc. filed its answer and counterclaims alleging that the patents are invalid, unenforceable and not infringed and Mylan Inc. and Mylan N.V. filed a motion to dismiss. Sprycel - U.S. In August 2019, BMS received a Notice Letter from Dr. Reddy’s Laboratories, Inc. notifying BMS that it had filed an aNDA containing paragraph IV certifications seeking approval of a generic version of Sprycel in the U.S. and challenging two FDA Orange Book-listed monohydrate form patents expiring in 2025 and 2026. In response, BMS initiated a patent infringement lawsuit under the Hatch-Waxman Act in the U.S. District Court for the District of New Jersey. No trial date has been set. In 2013, BMS entered into a settlement agreement with Apotex regarding a patent infringement suit covering the monohydrate form of dasatinib whereby Apotex can launch its generic dasatinib monohydrate aNDA product in September 2024 or earlier in certain circumstances. In March 2020, BMS received a Notice Letter from Teva notifying BMS that it had filed an aNDA containing paragraph IV certifications seeking approval of a generic version of Sprycel in the U.S. and challenging a FDA Orange Book-listed monohydrate form patent expiring in 2026. In response, BMS initiated a patent infringement lawsuit under the Hatch-Waxman Act in the U.S. District Court for the District of New Jersey. No trial date has been set. PRICING, SALES AND PROMOTIONAL PRACTICES LITIGATION Plavix* State Attorneys General Lawsuits BMS and certain Sanofi entities are defendants in consumer protection and/or false advertising actions brought by the attorneys general of Hawaii and New Mexico relating to the sales and promotion of Plavix. The Hawaii matter is currently scheduled for trial in October 2020. PRODUCT LIABILITY LITIGATION BMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. As previously disclosed, in addition to lawsuits, BMS also faces unfiled claims involving its products. Abilify BMS and Otsuka are co-defendants in product liability litigation related to Abilify. Plaintiffs allege Abilify caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional cases are pending in Canada. The Judicial Panel on Multidistrict Litigation consolidated the federal court cases for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master settlement agreement establishing a proposed settlement program to resolve all Abilify* compulsivity claims filed as of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., approximately 212 cases remain pending on behalf of 218 plaintiffs, who either chose not to participate in the settlement program or filed their claims after the settlement cut-off date. There are nine cases pending in Canada (four class actions, five individual injury claims). Out of the nine cases, only three are active (the class actions in Quebec and Ontario and one individual injury claim). Both class actions have now been certified and will proceed separately. Byetta* Amylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta. To date, there are approximately 584 separate lawsuits pending on behalf of approximately 2,234 active plaintiffs (including pending settlements), which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in federal court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles (“JCCP”). In November 2015, the defendants’ motion for summary judgment based on federal preemption was granted in both the MDL and the JCCP. In November 2017, the Ninth Circuit reversed the MDL summary judgment order and remanded the case to the MDL. In November 2018, the California Court of Appeal reversed the state court summary judgment order and remanded those cases to the JCCP for further proceedings. Amylin had product liability insurance covering a substantial number of claims involving Byetta* (which has been exhausted). As part of BMS’s global diabetes business divestiture, BMS sold Byetta* to AstraZeneca in February 2014 and any additional liability to Amylin with respect to Byetta* is expected to be shared with AstraZeneca. Onglyza* BMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza. Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza. As of April 2020, claims are pending in state and federal court on behalf of approximately 285 individuals who allege they ingested the product and suffered an injury. In February 2018, the Judicial Panel on Multidistrict Litigation ordered all federal cases to be transferred to an MDL in the U.S. District Court for the Eastern District of Kentucky. A significant majority of the claims are pending in the MDL. As part of BMS’s global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca. SECURITIES LITIGATION BMS Securities Class Action Since February 2018, two separate putative class action complaints were filed in the U.S. District for the Northern District of California and in the U.S. District Court for the Southern District of New York against BMS, BMS’s Chief Executive Officer, Giovanni Caforio, BMS’s Chief Financial Officer at the time, Charles A. Bancroft and certain former and current executives of BMS. The case in California has been voluntarily dismissed. The remaining complaint alleges violations of securities laws for BMS’s disclosures related to the CheckMate-026 clinical trial in lung cancer. In September 2019, the Court granted BMS’s motion to dismiss, but allowed the plaintiffs leave to file an amended complaint. In October 2019, the plaintiffs filed an amended complaint. BMS has moved to dismiss the amended complaint. Celgene Securities Class Action Beginning in March 2018, two putative class actions were filed against Celgene and certain of its officers in the U.S. District Court for the District of New Jersey (the “Celgene Securities Class Action”). The complaints allege that the defendants violated federal securities laws by making misstatements and/or omissions concerning (1) trials of GED-0301, (2) Celgene’s 2020 outlook and projected sales of Otezla, and (3) the new drug application for Zeposia (ozanimod). The Court consolidated the two actions and appointed a lead plaintiff, lead counsel, and co-liaison counsel for the putative class. In February 2019, the defendants filed a motion to dismiss plaintiff’s amended complaint in full. In December 2019, the Court denied the motion to dismiss in part and granted the motion to dismiss in part (including all claims arising from alleged misstatements regarding GED-0301). Although the Court gave the plaintiff leave to re-plead the dismissed claims, it elected not to do so, and the dismissed claims are now dismissed with prejudice. No trial date has been set for the claims that survived the Court’s order. In April 2020, certain Schwab management investment companies on behalf of certain Schwab funds filed an individual action in the U.S. District Court for the District of New Jersey asserting largely the same allegations as the Celgene Securities Class Action against the same remaining defendants in that action. The Company intends to vigorously defend against these claims. OTHER LITIGATION Average Manufacturer Price Litigation BMS is a defendant in a qui tam (whistleblower) lawsuit in the U.S. District Court for the Eastern District of Pennsylvania, in which the U.S. Government declined to intervene. The complaint alleges that BMS inaccurately reported its average manufacturer prices to the Centers for Medicare and Medicaid Services to lower what it owed. Similar claims have been filed against other companies. In January 2020, BMS reached an agreement in principle to resolve this matter subject to the negotiation of a definitive settlement agreement and other contingencies. BMS cannot provide assurances that its efforts to reach a final settlement will be successful. HIV Medication Antitrust Lawsuits BMS and several other manufacturers of HIV medications are defendants in related lawsuits brought by indirect purchasers in 2019 and direct purchasers in 2020 in the U.S. District Court for the Northern District of California, and by indirect purchasers in 2020 in the U.S. District Court for the Southern District of Florida, in each case alleging that the defendants’ agreements to develop and sell fixed-dose combination products for the treatment of HIV, including Atripla* and Evotaz, violate antitrust laws. The complaints allege additional theories of liability with respect to other defendants. The indirect purchaser complaint filed in Florida has been transferred and consolidated with the matters pending in the Northern District of California. In March 2020, in ruling on the defendants’ motions to dismiss the indirect purchasers’ complaint, the Court granted defendants’ motions to dismiss plaintiffs’ conspiracy claims but otherwise denied the motion to dismiss as to Gilead, BMS, and Janssen. Certain plaintiffs filed an amended complaint in April 2020. A trial is scheduled for February 2022. Humana Litigations On May 16, 2018, Humana, Inc. (“Humana”) filed a lawsuit against Celgene in the Pike County Circuit Court of the Commonwealth of Kentucky. Humana’s complaint alleges Celgene engaged in unlawful off-label marketing in connection with sales of Thalomid and Revlimid and asserts claims against Celgene for fraud, breach of contract, negligent misrepresentation, unjust enrichment and violations of New Jersey’s Racketeer Influenced and Corrupt Organizations Act. The complaint seeks, among other things, treble and punitive damages, injunctive relief and attorneys’ fees and costs. In April 2019, Celgene filed a motion to dismiss Humana’s complaint, which the Court denied in January 2020. No trial date has been set. On March 1, 2019, Humana filed a separate lawsuit against Celgene in the U.S. District Court for the District of New Jersey. Humana’s complaint alleges that Celgene violated various antitrust, consumer protection, and unfair competition laws to delay or prevent generic competition for Thalomid and Revlimid brand drugs, including (a) allegedly refusing to sell samples of products to generic manufacturers for purposes of bioequivalence testing intended to be included in aNDAs for approval to market generic versions of these products; (b) allegedly bringing unjustified patent infringement lawsuits, procuring invalid patents, and/or entering into anticompetitive patent settlements; (c) allegedly securing an exclusive supply contract for supply of thalidomide active pharmaceutical ingredient. The complaint purports to assert claims on behalf of Humana and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser, and seeks, among other things, treble and punitive damages, injunctive relief and attorneys’ fees and costs. Celgene filed a motion to dismiss Humana’s complaint, and the Court has stayed discovery pending adjudication of that motion. No trial date has been set. Thalomid and Revlimid Antitrust Class Action Litigation Beginning in November 2014, certain putative class action lawsuits were filed against Celgene in the U.S. District Court for the District of New Jersey alleging that Celgene violated various antitrust, consumer protection, and unfair competition laws by (a) allegedly securing an exclusive supply contract for the alleged purpose of preventing a generic manufacturer from securing its own supply of thalidomide active pharmaceutical ingredient, (b) allegedly refusing to sell samples of Thalomid and Revlimid brand drugs to various generic manufacturers for the alleged purpose of bioequivalence testing necessary for aNDAs to be submitted to the FDA for approval to market generic versions of these products, (c) allegedly bringing unjustified patent infringement lawsuits in order to allegedly delay approval for proposed generic versions of Thalomid and Revlimid, and/or (d) allegedly entering into settlements of patent infringement lawsuits with certain generic manufacturers that allegedly have had anticompetitive effects. The plaintiffs, on behalf of themselves and putative classes of third-party payers, are seeking injunctive relief and damages. The various lawsuits were consolidated into a master action for all purposes. In October 2017, the plaintiffs filed a motion for certification of two damages classes under the laws of thirteen states and the District of Columbia and a nationwide injunction class. Celgene filed an opposition to the plaintiffs’ motion and a motion for judgment on the pleadings dismissing all state law claims where the plaintiffs no longer seek to represent a class. In October 2018, the Court denied the plaintiffs’ motion for class certification and Celgene’s motion for judgment on the pleadings. In December 2018, the plaintiffs filed a new motion for class certification, which Celgene opposed. In July 2019, the parties reached a settlement under which all the putative class plaintiff claims would be dismissed with prejudice. In December 2019, after certain third-party payors who were members of the settlement class refused to release their potential claims and participate in the settlement, Celgene exercised its right to terminate the settlement agreement. In March 2020, Celgene reached a revised settlement with the class plaintiffs subject to approval by the Court. That settlement does not resolve the claims of certain entities that opted out of the first settlement. In March 2020, United HealthCare Services, Inc. (“UHS”), affiliates of which opted out of the first settlement in the Thalomid and Revlimid Antitrust Class Action Litigation, filed a lawsuit against Celgene in the U.S. District Court for the District of Minnesota. UHS’s complaint makes largely the same claims and allegations as the class action litigation. The complaint purports to assert claims on behalf of UHS and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser, and seeks, among other things, treble and punitive damages, injunctive relief and attorneys’ fees and costs. The Company intends to vigorously defend these claims. GOVERNMENT INVESTIGATIONS Like other pharmaceutical companies, BMS and certain of its subsidiaries are subject to extensive regulation by national, state and local authorities in the U.S. and other countries in which BMS operates. As a result, BMS, from time to time, is subject to various governmental and regulatory inquiries and investigations as well as threatened legal actions and proceedings. It is possible that criminal charges, substantial fines and/or civil penalties, could result from government or regulatory investigations. ENVIRONMENTAL PROCEEDINGS As previously reported, BMS is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including CERCLA, for certain costs of investigating and/or remediating contamination resulting from past industrial activity at BMS’s current or former sites or at waste disposal or reprocessing facilities operated by third parties. CERCLA Matters With respect to CERCLA matters for which BMS is responsible under various state, federal and foreign laws, BMS typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other “potentially responsible parties,” and BMS accrues liabilities when they are probable and reasonably estimable. BMS estimated its share of future costs for these sites to be $69.4 million at March 31, 2020, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties). The amount includes the estimated costs for any additional probable loss associated with the previously disclosed North Brunswick Township High School Remediation Site.

BASIS OF PRESENTATION (Policies)	3 Months Ended
BASIS OF PRESENTATION (Policies)	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidation, Policy [Policy Text Block]	Basis of Consolidation Bristol-Myers Squibb Company prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position at March 31, 2020 and December 31, 2019 and the results of operations and cash flows for the three months ended March 31, 2020 and 2019. All intercompany balances and transactions have been eliminated. BMS's consolidated financial statements include the assets, liabilities, operating results and cash flows of Celgene from the date of acquisition on November 20, 2019. These financial statements and the related notes should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2019 included in the 2019 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document.
Segment Reporting, Policy [Policy Text Block]	Business Segment Information BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Consistent with BMS's operational structure, the Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources at the global corporate level. Managing and allocating resources at the global corporate level enables the CEO to assess both the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or franchise basis. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods. For further information on product and regional revenue, see “—Note 2. Revenue.”
Use of Estimates, Policy [Policy Text Block]	Use of Estimates and Judgments Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining accounting for business combinations; impairments of intangible assets; sales rebate and return accruals; legal contingencies; and income taxes. Actual results may differ from estimates.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain reclassifications were made to conform the prior period interim consolidated financial statements to the current period presentation.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards Financial Instruments - Measurement of Credit Losses In June 2016, the FASB issued amended guidance for the measurement of credit losses on financial instruments. Entities will be required to use a forward-looking estimated loss model. Available-for-sale debt security credit losses will be recognized as allowances rather than a reduction in amortized cost. BMS adopted the amended guidance on a modified retrospective approach on January 1, 2020. The amended guidance did not impact BMS’s results of operations.

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2020

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following table summarizes the disaggregation of revenue by nature:



	Three Months Ended March 31,
Dollars in Millions	2020		2019
Net product sales	$	10,541	$	5,713
Alliance revenues	105		129
Other revenues	135		78
Total Revenues	$	10,781	$	5,920

Revenue Recognition, Discounts [Policy Text Block]

The following table summarizes GTN adjustments:



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Gross product sales	$	14,686		$	7,994
GTN adjustments^(a)
Charge-backs and cash discounts	(1,340		)	(774		)
Medicaid and Medicare rebates	(1,498		)	(800		)
Other rebates, returns, discounts and adjustments	(1,307		)	(707		)
Total GTN adjustments	(4,145		)	(2,281		)
Net product sales	$	10,541		$	5,713

(a)

Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $72 million and $78 million for the three months ended March 31, 2020 and 2019, respectively.

Revenue from External Customers by Products and Services [Table Text Block]

The following table summarizes the disaggregation of revenue by product and region:



	Three Months Ended March 31,
Dollars in Millions	2020		2019
Prioritized Brands
Revlimid	$	2,915	$	—
Eliquis	2,641		1,925
Opdivo	1,766		1,801
Orencia	714		640
Pomalyst/Imnovid	713		—
Sprycel	521		459
Yervoy	396		384
Abraxane	300		—
Empliciti	97		83
Reblozyl	8		—
Inrebic	12		—

Established Brands
Baraclude	122		141
Vidaza	158		—
Other Brands^(a)	418		487
Total Revenues	$	10,781	$	5,920

United States	$	6,766	$	3,449
Europe	2,567		1,480
Rest of the World	1,335		874
Other^(b)	113		117
Total Revenues	$	10,781	$	5,920


(a)	Includes BMS and Celgene products in 2020.

(b)

Other revenues include royalties and alliance-related revenues for products not sold by BMS's regional commercial organizations.

ALLIANCES (Tables)

3 Months Ended

Mar. 31, 2020

ALLIANCES [Abstract]

Collaborative Arrangement, Accounting Policy [Policy Text Block]



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Revenues from alliances:
Net product sales	$	2,723		$	2,378
Alliance revenues	105			129
Total Revenues	$	2,828		$	2,507

Payments to/(from) alliance partners:
Cost of products sold	$	1,306		$	1,019
Marketing, selling and administrative	(40		)	(28		)
Research and development	46			14
Other expense/(income), net	(15		)	(14		)



Dollars in Millions	March 31, 2020		December 31, 2019
Selected Alliance Balance Sheet information:
Receivables – from alliance partners	$	309	$	347
Accounts payable – to alliance partners	1,284		1,026
Deferred income from alliances^(a)	432		431

(a)

Includes unamortized upfront and milestone payments.

ACQUISITIONS, DIVESTITURES AND OTHER ARRANGEMENTS DIVESTITURES (Tables)

3 Months Ended

Mar. 31, 2020

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations [Table Text Block]

The following table summarizes the financial impact of divestitures including royalties, which are included in Other expense/(income), net. Revenue and pretax earnings related to all divestitures and assets held-for-sale were not material in all periods presented (excluding divestiture gains or losses).



	Three Months Ended March 31,
	Net Proceeds^(a)				Divestiture Gains					Royalty Income
Dollars in Millions	2020		2019		2020			2019		2020			2019
Diabetes Business	$	153	$	164	$	—		$	—	$	(127	)	$	(165	)
Erbitux*	4		5		—			—		—			—
Manufacturing Operations	—		2		(1		)	—		—			—
Plavix* and Avapro/Avalide	7		—		(12		)	—		—			—
Mature Brands and Other	31		—		(3		)	—		(31		)	(1		)
Total	$	195	$	171	$	(16	)	$	—	$	(158	)	$	(166	)

(a)

Includes royalties received subsequent to the related sale of the asset or business.

OTHER EXPENSE (INCOME), NET (Tables)

3 Months Ended

Mar. 31, 2020

Other Nonoperating Income (Expense) [Abstract]

Schedule Of Other Income Expense [Table Text Block]



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Interest expense	$	362		$	45
Pension and postretirement	(4		)	44
Royalties and licensing income	(410		)	(308		)
Divestiture gains	(16		)	—
Acquisition expenses	—			165
Contingent consideration	556			—
Investment income	(61		)	(56		)
Integration expenses	174			22
Provision for restructuring	160			12
Equity investment losses/(gains)	339			(175		)
Litigation and other settlements	32			1
Transition and other service fees	(61		)	(2		)
Reversion excise tax	76			—
Other	16			(9		)
Other expense/(income), net	$	1,163		$	(261	)

RESTRUCTURING (Tables)

3 Months Ended

Mar. 31, 2020

Celgene Integration [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Costs [Table Text Block]

The following tables summarize the charges and activity related to the Celgene acquisition:



Dollars in Millions	Three Months Ended March 31, 2020
Employee termination costs	$	146
Other termination costs	4
Provision for restructuring	150
Integration expenses	174
Total charges^(a)	$	324

(a)

Included in Other expense/(income), net.

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]



Dollars in Millions	Three Months Ended March 31, 2020
Liability at January 1	$	77
Charges	131
Change in estimates	1
Provision for restructuring^(a)	132
Foreign currency translation and other	6
Payments	(91		)
Liability at March 31	$	124


(a)	Excludes $18 million of accelerated stock-based compensation.

Operating Model 2020 [Member]

Restructuring Cost and Reserve [Line Items]

Restructuring and Related Costs [Table Text Block]

The following tables summarize the charges and activity related to the Company transformation:



	Three Months Ended March 31,
Dollars in Millions	2020		2019
Employee termination costs	$	3	$	4
Other termination costs	7		8
Provision for restructuring	10		12
Accelerated depreciation	30		31
Asset impairments	42		1
Total charges	$	82	$	44



	Three Months Ended March 31,
Dollars in Millions	2020		2019
Cost of products sold	$	16	$	12
Marketing, selling and administrative	—		1
Research and development	56		19
Other expense/(income), net	10		12
Total charges	$	82	$	44

Schedule of Restructuring Reserve by Type of Cost [Table Text Block]



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Liability at December 31	$	23		$	99
Cease-use liability reclassification	—			(3		)
Liability at January 1	23			96
Charges	7			15
Change in estimates	3			(3		)
Provision for restructuring	10			12
Payments	(16		)	(45		)
Liability at March 31	$	17		$	63

INCOME TAXES (Tables)

3 Months Ended

Mar. 31, 2020

Income Tax Disclosure [Abstract]

Schedule of Provision for Income Taxes [Table Text Block]



	Three Months Ended March 31,
Dollars in Millions	2020			2019
(Loss)/Earnings Before Income Taxes	$	(304	)	$	1,979
Provision for Income Taxes	462			264
Effective Tax Rate	(152.0		)%	13.3		%

EARNINGS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2020

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]



	Three Months Ended March 31,
Amounts in Millions, Except Per Share Data	2020			2019
Net (Loss)/Earnings Attributable to BMS Used for Basic and Diluted EPS Calculation	$	(775	)	$	1,710

Weighted-Average Common Shares Outstanding – Basic	2,258			1,634
Incremental Shares Attributable to Share-Based Compensation Plans	—			3
Weighted-Average Common Shares Outstanding – Diluted	2,258			1,637

(Loss)/Earnings per Common Share
Basic	$	(0.34	)	$	1.05
Diluted	(0.34		)	1.04

The total number of potential shares of common stock excluded from the diluted EPS computation because of the antidilutive impact was 138 million for the three months ended March 31, 2020.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2020

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

Financial assets and liabilities measured at fair value on a recurring basis are summarized below:



	March 31, 2020							December 31, 2019
Dollars in Millions	Level 1		Level 2			Level 3		Level 1		Level 2			Level 3
Cash and cash equivalents - money market and other securities	$	—	$	13,528		$	—	$	—	$	10,448		$	—
Marketable debt securities:
Certificates of deposit	—		1,062			—		—		1,227			—
Commercial paper	—		869			—		—		1,093			—
Corporate debt securities	—		1,225			—		—		1,494			—
Derivative assets			202					—		140			—
Equity investments	1,822		145			—		2,020		175			—
Derivative liabilities	—		(29		)	—		—		(40		)	—
Contingent consideration liability:
Contingent value rights	2,862		—			—		2,275		—			—
Other acquisition related contingent consideration	—		—			69		—		—			106

Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]

The fair value of our contingent consideration as of March 31, 2020 was calculated using the following significant unobservable inputs:



	Ranges (weighted average) utilized as of:
Inputs	March 31, 2020
Discount rate	2.2% to 2.7% (2.4%)
Probability of payment	0% to 80% (2.6%)
Projected year of payment for development and regulatory milestones	2020 to 2029 (2022)
Projected year of payment for sales-based milestones and other amounts calculated as a percentage of annual sales	N/A

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

The following table represents a roll-forward of the fair value of level 3 instruments:



Dollars in Millions	Three Months Ended March 31, 2020
Fair value as of January 1	$	106
Changes in estimated fair value	(36		)
Foreign exchange	(1		)
Fair value as of March 31	$	69

Available-for-sale Securities [Table Text Block]

Changes in fair value of equity investments are included in Other expense/(income), net. The following table summarizes available-for-sale debt securities and equity investments:



	March 31, 2020									December 31, 2019
Dollars in Millions	Amortized Cost		Gross Unrealized							Amortized Cost		Gross Unrealized
Dollars in Millions	Amortized Cost		Gains		Losses			Fair Value		Amortized Cost		Gains		Losses			Fair Value
Certificates of deposit	$	1,062	$	—	$	—		$	1,062	$	1,227	$	—	$	—		$	1,227
Commercial paper	869		—		—			869		1,093		—		—			1,093
Corporate debt securities	1,216		11		(2		)	1,225		1,487		8		(1		)	1,494
	$	3,147	$	11	$	(2	)	3,156		$	3,807	$	8	$	(1	)	3,814

Equity investments								1,967									2,195
Total								$	5,123								$	6,009



Dollars in Millions	March 31, 2020		December 31, 2019
Marketable debt securities - current	$	2,505	$	3,047
Marketable debt securities - non-current^(a)	651		767
Other non-current assets	1,967		2,195
Total	$	5,123	$	6,009


(a)	All non-current marketable debt securities mature within five years as of March 31, 2020 and December 31, 2019.

Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table Text Block]

The following table summarizes the net (loss)/gain recorded for equity investments with readily determinable fair values held as of March 31, 2020 and 2019:



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Net (loss)/gain recognized	$	(228	)	$	95
Less: Net gain recognized for equity investments sold	—			14
Net unrealized (loss)/gain on equity investments held	$	(228	)	$	81

Schedule of Derivatives and Fair Value [Table Text Block]

The following table summarizes the fair value of outstanding derivatives:



	March 31, 2020									December 31, 2019
	Asset^(a)				Liability^(b)					Asset^(a)				Liability^(b)
Dollars in Millions	Notional		Fair Value		Notional		Fair Value			Notional		Fair Value		Notional		Fair Value
Derivatives designated as hedging instruments:
Interest rate swap contracts	$	255	$	25	$	—	$	—		$	255	$	6	$	—	$	—
Cross-currency interest rate swap contracts	400		7		—		—			175		2		125		(1		)
Foreign currency forward contracts	2,383		75		301		(2		)	766		27		980		(20		)

Derivatives not designated as hedging instruments:
Foreign currency forward contracts	1,177		73		772		(19		)	2,342		91		1,173		(10		)
Foreign currency zero-cost collar contracts	1,522		22		1,597		(8		)	2,482		14		2,235		(9		)


(a)	Included in Other current assets and Other non-current assets.

(b)

Included in Other current liabilities and Other non-current liabilities.

Derivative Instruments, Gain (Loss) [Table Text Block]

The following table summarizes the financial statement classification and amount of (gain)/loss recognized on hedging instruments:



	Three Months Ended March 31, 2020
Dollars in Millions	Cost of products sold			Other expense/(income), net
Interest rate swap contracts	$	—		$	(7	)
Cross-currency interest rate swap contracts	—			(2		)
Foreign currency forward contracts	(23		)	(76		)
Foreign currency zero-cost collar contracts	—			(9		)



	Three Months Ended March 31, 2019
Dollars in Millions	Cost of products sold			Other expense/(income), net
Interest rate swap contracts	$	—		$	(5	)
Cross-currency interest rate swap contracts	—			(2		)
Foreign currency forward contracts	(30		)	9
Forward starting interest rate swap options	—			35

Gain/(Loss) on Hedging Activity [Table Text Block]

The following table summarizes the effect of derivative and non-derivative instruments designated as hedging instruments in Other Comprehensive (Loss)/Income:



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Derivatives qualifying as cash flow hedges
Foreign currency forward contracts gain/(loss):
Recognized in Other Comprehensive (Loss)/Income^(a)	$	97		$	45
Reclassified to Cost of products sold	(20		)	(30		)

Derivatives qualifying as net investment hedges
Cross-currency interest rate swap contracts gain:
Recognized in Other Comprehensive (Loss)/Income	6			6

Non-derivatives qualifying as net investment hedges
Non-U.S. dollar borrowings gain:
Recognized in Other Comprehensive (Loss)/Income	20			8

(a)

The amount is expected to be reclassified into earnings in the next 12 months.

Schedule of Short-term Debt [Table Text Block]

Short-term debt obligations include:



Dollars in Millions	March 31, 2020		December 31, 2019
Non-U.S. short-term borrowings	$	345	$	351
Current portion of long-term debt	3,261		2,763
Other	256		232
Total	$	3,862	$	3,346

Schedule of Fair Value and Other Adjustments to Long Term Debt [Table Text Block]

Long-term debt and the current portion of long-term debt include:



Dollars in Millions	March 31, 2020			December 31, 2019
Principal Value	$	44,310		$	44,335

Adjustments to Principal Value:
Fair value of interest rate swap contracts	25			6
Unamortized basis adjustment from swap terminations	168			175
Unamortized bond discounts and issuance costs	(271		)	(280		)
Unamortized purchase price adjustments of Celgene debt	1,873			1,914
Total	$	46,105		$	46,150

Current portion of long-term debt	$	3,261		$	2,763
Long-term debt	42,844			43,387
Total	$	46,105		$	46,150

RECEIVABLES (Tables)

3 Months Ended

Mar. 31, 2020

Accounts Receivable, after Allowance for Credit Loss [Abstract]

Schedule Of Receivables [Table Text Block]



Dollars in Millions	March 31, 2020			December 31, 2019
Trade receivables	$	7,660		$	6,888
Less charge-backs and cash discounts	(437		)	(391		)
Less bad debt allowances	(23		)	(21		)
Net trade receivables	7,200			6,476
Alliance, royalties, VAT and other	1,090			1,209
Receivables	$	8,290		$	7,685

INVENTORIES (Tables)

3 Months Ended

Mar. 31, 2020

Inventory, Net [Abstract]

Inventories [Table Text Block]



Dollars in Millions	March 31, 2020		December 31, 2019
Finished goods	$	1,283	$	2,227
Work in process	2,651		3,267
Raw and packaging materials	164		172
Total inventories	$	4,098	$	5,666

Inventories	$	2,836	$	4,293
Other non-current assets	1,262		1,373

PROPERTY, PLANT AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2020

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]



Dollars in Millions	March 31, 2020			December 31, 2019
Land	$	194		$	187
Buildings	5,848			6,336
Machinery, equipment and fixtures	3,055			3,157
Construction in progress	456			527
Gross property, plant and equipment	9,553			10,207
Less accumulated depreciation	(3,441		)	(3,955		)
Property, plant and equipment	$	6,112		$	6,252

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule Of Intangible Assets By Major Class [Table Text Block]



Dollars in Millions	Estimated Useful Lives	March 31, 2020			December 31, 2019
Goodwill^(a)		$	22,452		$	22,488

Other intangible assets:
Licenses	5 – 15 years	482			482
Acquired developed product rights	3 – 15 years	50,427			46,827
Capitalized software	3 – 10 years	1,263			1,297
IPRD		15,900			19,500
Gross other intangible assets		68,072			68,106
Less accumulated amortization		(6,406		)	(4,137		)
Other intangible assets		$	61,666		$	63,969

(a)

Includes measurement period adjustments. Refer to “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for more information.

Supplemental Financial Information (Tables)

3 Months Ended

Mar. 31, 2020

Supplemental Financial Information [Abstract]

Schedule of Other Current Assets [Table Text Block]



Dollars in Millions	March 31, 2020		December 31, 2019
Prepaid and refundable income taxes	$	999	$	754
Research and development	445		410
Other	961		819
Other current assets	$	2,405	$	1,983

Schedule of Other Assets, Noncurrent [Table Text Block]



Dollars in Millions	March 31, 2020		December 31, 2019
Equity investments	$	3,144	$	3,405
Inventories	1,262		1,373
Operating leases	724		704
Pension and postretirement	189		456
Restricted cash^(a)	342		390
Other	285		276
Other non-current assets	$	5,946	$	6,604

(a)

Restricted cash consists of escrow for litigation settlements and funds restricted for annual Company contributions to the defined contribution plan in the U.S. Restricted cash of $429 million was included in cash, cash equivalents and restricted cash at March 31, 2020 in the consolidated statements of cash flows.

Schedule of Accrued Liabilities [Table Text Block]



Dollars in Millions	March 31, 2020		December 31, 2019
Rebates and returns	$	4,407	$	4,275
Income taxes payable	1,996		1,517
Employee compensation and benefits	678		1,457
Research and development	1,308		1,324
Dividends	1,037		1,025
Interest	393		493
Royalties	328		418
Operating leases	136		133
Other	2,018		1,871
Other current liabilities	$	12,301	$	12,513

Other Noncurrent Liabilities [Table Text Block]



Dollars in Millions	March 31, 2020		December 31, 2019
Income taxes payable	$	5,364	$	5,368
Contingent value rights	2,862		2,275
Pension and postretirement	841		725
Operating leases	688		672
Deferred income	394		424
Deferred compensation	254		287
Other	298		350
Other non-current liabilities	$	10,701	$	10,101

EQUITY (Tables)

3 Months Ended

Mar. 31, 2020

Equity [Abstract]

Schedule of Stock by Class [Table Text Block]

The following table summarizes changes in equity for the three months ended March 31, 2020:



	Common Stock			Capital in Excess of Par Value of Stock			Accumulated Other Comprehensive Loss			Retained Earnings			Treasury Stock					Noncontrolling Interest
Dollars and Shares in Millions	Shares	Par Value		Capital in Excess of Par Value of Stock			Accumulated Other Comprehensive Loss			Retained Earnings			Shares		Cost			Noncontrolling Interest
Balance at December 31, 2019	2,923	$	292	$	43,709		$	(1,520	)	$	34,474		672		$	(25,357	)	$	100
Net loss	—	—		—			—			(775		)	—		—			9
Other Comprehensive Loss	—	—		—			(29		)	—			—		—			—
Cash dividends declared^(a)	—	—		—			—			(1,028		)	—		—			—
Share repurchase program	—	—		—			—			—			1		(81		)	—
Stock compensation	—	—		(455		)	—			—			(13	)	681			—
Distributions	—	—		—			—			—			—		—			(43		)
Balance at March 31, 2020	2,923	$	292	$	43,254		$	(1,549	)	$	32,671		660		$	(24,757	)	$	66


(a)	Cash dividends declared per common share were $0.45 for the three months ended March 31, 2020.

The following table summarizes changes in equity for the three months ended March 31, 2019:



	Common Stock			Capital in Excess of Par Value of Stock		Accumulated Other Comprehensive Loss			Retained Earnings			Treasury Stock					Noncontrolling Interest
Dollars and Shares in Millions	Shares	Par Value		Capital in Excess of Par Value of Stock		Accumulated Other Comprehensive Loss			Retained Earnings			Shares		Cost			Noncontrolling Interest
Balance at December 31, 2018	2,208	$	221	$	2,081	$	(2,762	)	$	34,065		576		$	(19,574	)	$	96
Accounting change - cumulative effect^(a)	—	—		—		—			5			—		—			—
Adjusted balance at January 1, 2019	2,208	221		2,081		(2,762		)	34,070			576		(19,574		)	96
Net earnings	—	—		—		—			1,710			—		—			5
Other Comprehensive Income	—	—		—		118			—			—		—			—
Cash dividends declared^(b)	—	—		—		—			(671		)	—		—			—
Stock compensation	—	—		22		—			—			(4	)	3			—
Distributions	—	—		—		—			—			—		—			(2		)
Balance at March 31, 2019	2,208	$	221	$	2,103	$	(2,644	)	$	35,109		572		$	(19,571	)	$	99


(a)	Refer to “—Note 1. Accounting Policies and Recently Issued Accounting Standards” in the Company's 2019 Form 10-K for additional information.


(b)	Cash dividends declared per common share were $0.41 for the three months ended March 31, 2019.

Schedule of Comprehensive Income Loss [Table Text Block]

The components of Other Comprehensive (Loss)/Income were as follows:



	2020									2019
Dollars in Millions	Pretax			Tax			After Tax			Pretax			Tax			After Tax
Three Months Ended March 31,
Derivatives qualifying as cash flow hedges:
Unrealized gains/(losses)	$	97		$	(10	)	$	87		$	45		$	(5	)	$	40
Reclassified to net earnings^(a)	(20		)	3			(17		)	(30		)	4			(26		)
Derivatives qualifying as cash flow hedges	77			(7		)	70			15			(1		)	14

Pension and postretirement benefits:
Actuarial gains/(losses)	8			(2		)	6			(2		)	—			(2		)
Amortization^(b)	9			(1		)	8			17			(4		)	13
Settlements^(b)	2			—			2			49			(11		)	38
Pension and postretirement benefits	19			(3		)	16			64			(15		)	49

Available-for-sale debt securities:
Unrealized gains	2			(1		)	1			23			—			23
Realized losses	—			—			—			3			—			3
Available-for-sale debt securities	2			(1		)	1			26			—			26

Foreign currency translation	(110		)	(6		)	(116		)	32			(3		)	29

Other Comprehensive (Loss)/Income	$	(12	)	$	(17	)	$	(29	)	$	137		$	(19	)	$	118


(a)	Included in Cost of products sold.


(b)	Included in Other expense/(income), net.

Schedule of Accumulated Other Comprehensive Income Loss [Table Text Block]

The accumulated balances related to each component of Other Comprehensive (Loss)/Income, net of taxes, were as follows:



Dollars in Millions	March 31, 2020			December 31, 2019
Derivatives qualifying as cash flow hedges	$	89		$	19
Pension and postretirement benefits	(883		)	(899		)
Available-for-sale debt securities	7			6
Foreign currency translation	(762		)	(646		)
Accumulated other comprehensive loss	$	(1,549	)	$	(1,520	)

PENSION AND POSTRETIREMENT BENEFIT PLANS (Tables)

3 Months Ended

Mar. 31, 2020

Retirement Benefits [Abstract]

Schedule of Net Benefit Costs [Table Text Block]

The net periodic benefit cost of defined benefit pension plans includes:



	Three Months Ended March 31,
Dollars in Millions	2020			2019
Service cost – benefits earned during the year	$	12		$	7
Interest cost on projected benefit obligation	8			44
Expected return on plan assets	(23		)	(64		)
Amortization of prior service credits	(1		)	(1		)
Amortization of net actuarial loss	11			18
Curtailments and settlements	2			49
Net periodic pension benefit cost	$	9		$	53

EMPLOYEE STOCK BENEFIT PLANS Employee Stock Benefit Plans (Tables)

3 Months Ended

Mar. 31, 2020

Share-based Payment Arrangement, Disclosure [Abstract]

Share-based Payment Arrangement, Cost by Plan [Table Text Block]

Stock-based compensation expense was as follows:



	Three Months Ended March 31,
Dollars in Millions	2020		2019
Cost of products sold	$	10	$	4
Marketing, selling and administrative	88		30
Research and development	94		19
Other expense/(income), net	18		—
Total stock-based compensation expense	$	210	$	53

Income tax benefit^(a)	$	46	$	10

(a)

Income tax benefit excludes excess tax benefits of $23 million and $2 million from share-based compensation awards that were vested or exercised during the three months ended March 31, 2020 and 2019, respectively.

Schedule Of Share Based Compensation Additional Information [Table Text Block]

The number of units granted and the weighted-average fair value on the grant date for the three months ended March 31, 2020 were as follows:



Units in Millions	Units	Weighted-Average Fair Value
Restricted stock units	12.5	$	53.63
Market share units	0.9	53.88
Performance share units	1.4	55.66

Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]



Dollars in Millions	Stock Options		Restricted Stock Units		Market Share Units		Performance Share Units
Unrecognized compensation cost	$	92	$	1,397	$	77	$	135
Expected weighted-average period in years of compensation cost to be recognized	1.9		2.9		3.4		2.1

REVENUE RECOGNITION Revenue by Nature (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 10,781	$ 5,920
Net product sales [Member]
Disaggregation of Revenue [Line Items]
Revenues	10,541	5,713
Other revenues [Member]
Disaggregation of Revenue [Line Items]
Revenues	135	78
Collaborative Arrangement [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,828	2,507
Collaborative Arrangement [Member] \| Net product sales [Member]
Disaggregation of Revenue [Line Items]
Revenues	2,723	2,378
Collaborative Arrangement [Member] \| Collaborative Arrangement [Member]
Disaggregation of Revenue [Line Items]
Revenues	$ 105	$ 129

REVENUE RECOGNITION Gross-to-Net Adjustments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Gross to Net Adjustments [Line Items]
Revenues	$ 10,781	$ 5,920
Gross to Net Adjustments	(4,145)	(2,281)
Prior Period Gross to Net Adjustment Impacted by New Accounting Pronouncement	72	78
Sales Revenue, Gross [Member]
Gross to Net Adjustments [Line Items]
Revenues	14,686	7,994
Net product sales [Member]
Gross to Net Adjustments [Line Items]
Revenues	10,541	5,713
Charge-backs and cash discounts [Member]
Gross to Net Adjustments [Line Items]
Gross to Net Adjustments	(1,340)	(774)
Medicaid and Medicare rebates [Member]
Gross to Net Adjustments [Line Items]
Gross to Net Adjustments	(1,498)	(800)
Other rebates, returns, discounts and adjustments [Member]
Gross to Net Adjustments [Line Items]
Gross to Net Adjustments	$ (1,307)	$ (707)

REVENUE RECOGNITION Revenue by Product by Region (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue from External Customer [Line Items]
Revenues	$ 10,781	$ 5,920
Revlimid [Member]
Revenue from External Customer [Line Items]
Revenues	2,915	0
Eliquis [Member]
Revenue from External Customer [Line Items]
Revenues	2,641	1,925
Opdivo [Member]
Revenue from External Customer [Line Items]
Revenues	1,766	1,801
Orencia [Member]
Revenue from External Customer [Line Items]
Revenues	714	640
Pomalyst/Imnovid [Member]
Revenue from External Customer [Line Items]
Revenues	713	0
Sprycel [Member]
Revenue from External Customer [Line Items]
Revenues	521	459
Yervoy [Member]
Revenue from External Customer [Line Items]
Revenues	396	384
Abraxane [Member]
Revenue from External Customer [Line Items]
Revenues	300	0
Empliciti [Member]
Revenue from External Customer [Line Items]
Revenues	97	83
Reblozyl [Member]
Revenue from External Customer [Line Items]
Revenues	8	0
Inrebic [Member]
Revenue from External Customer [Line Items]
Revenues	12	0
Baraclude [Member]
Revenue from External Customer [Line Items]
Revenues	122	141
Vidaza [Member]
Revenue from External Customer [Line Items]
Revenues	158	0
Mature Products And All Other [Member]
Revenue from External Customer [Line Items]
Revenues	418	487
UNITED STATES
Revenue from External Customer [Line Items]
Revenues	6,766	3,449
European Union [Member]
Revenue from External Customer [Line Items]
Revenues	2,567	1,480
Rest Of World [Member]
Revenue from External Customer [Line Items]
Revenues	1,335	874
Other Region [Member]
Revenue from External Customer [Line Items]
Revenues	$ 113	$ 117

REVENUE RECOGNITION Narratives (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue, Performance Obligation [Abstract]
Contract with Customer, Performance Obligation Satisfied in Previous Period	$ 130	$ 147

ALLIANCES (Details) - USD ($)
$ in Millions

3 Months Ended

Mar. 31, 2020

Mar. 31, 2019

Dec. 31, 2019

Alliance Statement [Line Items]

Revenues

$ 10,781

$ 5,920

Cost of Goods and Services Sold

^[1]

3,662

1,824

Other Nonoperating (Income) Expense

1,163

(261)

Receivables

8,290

$ 7,685

Accounts payable

3,069

2,445

Collaborative Arrangement [Member]

Alliance Statement [Line Items]

Revenues

2,828

2,507

Cost of Goods and Services Sold

1,306

1,019

Selling, General and Administrative Expense - Collaborative Arrangement

(40)

(28)

Research and Development Expense - Collaborative Arrangement

46

14

Other Nonoperating (Income) Expense

(15)

(14)

Receivables

309

347

Accounts payable

1,284

1,026

Deferred income from alliances

432

$ 431

Net product sales [Member]

Alliance Statement [Line Items]

Revenues

10,541

5,713

Net product sales [Member] | Collaborative Arrangement [Member]

Alliance Statement [Line Items]

Revenues

2,723

2,378

Collaborative Arrangement [Member] | Collaborative Arrangement [Member]

Alliance Statement [Line Items]

Revenues

$ 105

$ 129

[1]	Excludes amortization of acquired intangible assets

ACQUISITIONS, DIVESTITURES AND OTHER ARRANGEMENTS ACQUISITIONS (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($)
Business Combinations [Abstract]
Goodwill, Purchase Accounting Adjustments	$ 22
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Equity Interests	58
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Financial Liabilities	$ 30

DIVESTITURES (Details) - USD ($) $ in Millions	3 Months Ended
DIVESTITURES (Details) - USD ($) $ in Millions	Mar. 31, 2020	Mar. 31, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	$ 195	$ 171
Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal	(16)	0
Royalty Income, Nonoperating	(158)	(166)
Diabetes business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	153	164
Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal	0	0
Royalty Income, Nonoperating	(127)	(165)
Erbitux [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	4	5
Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal	0	0
Royalty Income, Nonoperating	0	0
Manufacturing Facility [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	0	2
Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal	(1)	0
Royalty Income, Nonoperating	0	0
Avapro, Avalide, and Plavix [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	7	0
Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal	(12)	0
Royalty Income, Nonoperating	0	0
Other divestitures [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested	31	0
Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal	(3)	0
Royalty Income, Nonoperating	$ (31)	$ (1)

OTHER EXPENSE (INCOME), NET (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Other Nonoperating Income (Expense) [Abstract]
Interest expense	$ 362	$ 45
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	(4)	44
Royalties and licensing income	(410)	(308)
Disposal Group, Not Discontinued Operation, (Gain) Loss on Disposal	(16)	0
Business Acquisition, Transaction Costs	0	165
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	556	0
Investment income	(61)	(56)
Business Combination, Integration Related Costs	174	22
Restructuring Charges	160	12
Equity investment, (gain) loss	339	(175)
Litigation and other settlements	32	1
Transition and other service fees	(61)	(2)
Reversion excise tax	76	0
Other	16	(9)
Other Nonoperating (Income) Expense	$ 1,163	$ (261)

RESTRUCTURING NARRATIVE (Details) $ in Billions	3 Months Ended
RESTRUCTURING NARRATIVE (Details) $ in Billions	Mar. 31, 2020 USD ($)
Operating Model 2020 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	$ 1.5
Operating Model 2020 [Member] \| Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	$ 1.6
Cash outlays percentage	40.00%
Operating Model 2020 [Member] \| Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	$ 2.0
Cash outlays percentage	50.00%
Celgene Integration [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	$ 1.0
Cash outlays	$ 2.5
Restructuring and Related Cost, Number of Positions Eliminated	600
Celgene Integration [Member] \| Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	$ 2.8
Celgene Integration [Member] \| Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	$ 3.0

RESTRUCTURING RESTRUCTURING AND RELATED COSTS TABLE (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 160	$ 12
Business Combination, Integration Related Costs	174	22
Operating Model 2020 [Member]
Restructuring Cost and Reserve [Line Items]
Severance Costs	3	4
Other Restructuring Costs	7	8
Restructuring Charges	10	12
Restructuring and Related Cost, Accelerated Depreciation	30	31
Restructuring Related Costs, Asset Impairments	42	1
Restructuring Costs and Asset Impairment Charges	82	44
Operating Model 2020 [Member] \| Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs and Asset Impairment Charges	16	12
Operating Model 2020 [Member] \| Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs and Asset Impairment Charges	0	1
Operating Model 2020 [Member] \| Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs and Asset Impairment Charges	56	19
Operating Model 2020 [Member] \| Other Nonoperating Income (Expense) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs and Asset Impairment Charges	10	$ 12
Celgene Integration [Member]
Restructuring Cost and Reserve [Line Items]
Severance Costs	146
Other Restructuring Costs	4
Restructuring Charges	150
Business Combination, Integration Related Costs	174
Celgene Integration [Member] \| Other Nonoperating Income (Expense) [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs and Asset Impairment Charges	$ 324

RESTRUCTURING SCHEDULE OF RESTRUCTURING RESERVE (Details) - USD ($) $ in Millions			3 Months Ended
	Jan. 01, 2020	Jan. 01, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Restructuring Charges			$ 160	$ 12
Operating Model 2020 [Member]
Restructuring Reserve	$ 23	$ 96	17	63	$ 23	$ 99
Restructuring Reserve, Translation and Other Adjustment	0	$ (3)
Restructuring Reserve, Period Increase (Decrease)			7	15
Restructuring Reserve, Accrual Adjustment			3	(3)
Restructuring Charges			10	12
Payments for Restructuring			(16)	$ (45)
Celgene Integration [Member]
Restructuring Reserve	$ 77		124
Restructuring Reserve, Period Increase (Decrease)			131
Restructuring Reserve, Accrual Adjustment			1
Restructuring Charges Exclude Accelerated Stock-Based Compensation			132
Restructuring Charges			150
Payments for Restructuring			(91)
Restructuring Reserve, Foreign Currency Translation Gain (Loss)			6
Celgene Integration [Member] \| Accelerated Stock Based Compensation [Member]
Restructuring Charges			$ 18

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended
INCOME TAXES (Details) - USD ($) $ in Millions	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Line Items]
Earnings Before Income Taxes	$ (304)	$ 1,979
Income Tax Expense (Benefit)	$ 462	$ 264
Effective Income Tax Rate Reconciliation, Percent	(152.00%)	13.30%
Document Period End Date	Mar. 31, 2020
Minimum [Member]
Income Tax Disclosure [Line Items]
Decrease in Unrecognized Tax Benefits is Reasonably Possible	$ 290
Maximum [Member]
Income Tax Disclosure [Line Items]
Decrease in Unrecognized Tax Benefits is Reasonably Possible	$ 330

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Earnings Per Share [Abstract]
Net earnings attributable to BMS used for Basic and Diluted EPS Calculation	$ (775)	$ 1,710
Weighted-average common shares outstanding - basic	2,258	1,634
Incremental shares attributable to share-based compensation plans	0	3
Weighted-average common shares outstanding - diluted	2,258	1,637
Earnings Per Share, Basic	$ (0.34)	$ 1.05
Earnings Per Share, Diluted	$ (0.34)	$ 1.04
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	138

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Fair Value Measurement) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($) percentage	Mar. 31, 2019 USD ($)	Jan. 01, 2020 USD ($)	Dec. 31, 2019 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	$ 3,156			$ 3,814
Equity Securities, FV-NI	1,967			2,195
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	556	$ 0
Debt Securities, Available-for-sale, Amortized Cost	3,147			3,807
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	11			8
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(2)			(1)
Total securities	5,123			6,009
Investments, Fair Value Disclosure	5,123			6,009
Equity Securities without Readily Determinable Fair Value, Amount	754			781
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount	75
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount	188
Equity Securities, FV-NI, Gain (Loss)	(228)	95
Equity Securities, FV-NI, Realized Gain (Loss)	0	14
Equity Securities, FV-NI, Unrealized Gain (Loss)	(228)	$ 81
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0			0
Derivative asset				0
Derivative Liability	0			0
Business Combination, Contingent Consideration, Liability	0			0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	13,528			10,448
Derivative asset	202			140
Derivative Liability	(29)			(40)
Business Combination, Contingent Consideration, Liability	0			0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0			0
Derivative asset				0
Derivative Liability	0			0
Business Combination, Contingent Consideration, Liability	69		$ 106	106
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	(36)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Due to Foreign Exchange, Liability	(1)
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	1,062			1,227
Debt Securities, Available-for-sale, Amortized Cost	1,062			1,227
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0			0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0			0
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0			0
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	1,062			1,227
Certificates of Deposit [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0			0
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	869			1,093
Debt Securities, Available-for-sale, Amortized Cost	869			1,093
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0			0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0			0
Commercial Paper [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0			0
Commercial Paper [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	869			1,093
Commercial Paper [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0			0
Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	1,225			1,494
Debt Securities, Available-for-sale, Amortized Cost	1,216			1,487
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	11			8
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	(2)			(1)
Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0			0
Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	1,225			1,494
Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	0			0
Marketable debt securities - current [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	2,505			3,047
Marketable debt securities - non-current [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	651			767
Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,967			2,195
Other Assets [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI	1,822			2,020
Other Assets [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI	145			175
Other Assets [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI	0			0
Portion at Other than Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investments	424			429
Contingent Value Rights [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	2,862			2,275
Contingent Value Rights [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	2,862			2,275
Contingent Value Rights [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	0			0
Contingent Value Rights [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	$ 0			$ 0
Probability of payment [Member] \| Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Measurement Input \| percentage	0.8
Probability of payment [Member] \| Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Measurement Input \| percentage	0.026
Probability of payment [Member] \| Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Measurement Input \| percentage	0
Measurement Input, Discount Rate [Member] \| Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Measurement Input \| percentage	0.027
Measurement Input, Discount Rate [Member] \| Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Measurement Input \| percentage	0.024
Measurement Input, Discount Rate [Member] \| Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Measurement Input \| percentage	0.022

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Derivatives and Hedging) (Details) € in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Mar. 31, 2020 EUR (€)	Dec. 31, 2019 USD ($)
Derivative [Line Items]
Debt Instrument, Face Amount	$ 44,310.0			$ 44,335.0
Derivative, Basis Spread on Variable Rate	4.60%		4.60%
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax	$ 97.0	$ 45.0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(20.0)	(30.0)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax	(110.0)	32.0
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Debt Instrument, Face Amount	1,000.0		€ 950
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax	20.0	8.0
Interest Rate Swap [Member]
Derivative [Line Items]
Derivative Liability	25.0			6.0
Interest Rate Swap [Member] \| Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative asset	25.0			6.0
Derivative Liability	0.0			0.0
Interest Rate Swap [Member] \| Designated as Hedging Instrument [Member] \| Assets [Member]
Derivative [Line Items]
Derivative, Notional Amount	255.0			255.0
Interest Rate Swap [Member] \| Designated as Hedging Instrument [Member] \| Liability [Member]
Derivative [Line Items]
Derivative, Notional Amount	0.0			0.0
Cross Currency Interest Rate Contract [Member]
Derivative [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax	6.0	6.0
Cross Currency Interest Rate Contract [Member] \| Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative asset	7.0			2.0
Derivative Liability	0.0			(1.0)
Cross Currency Interest Rate Contract [Member] \| Designated as Hedging Instrument [Member] \| Assets [Member]
Derivative [Line Items]
Derivative, Notional Amount	400.0			175.0
Cross Currency Interest Rate Contract [Member] \| Designated as Hedging Instrument [Member] \| Liability [Member]
Derivative [Line Items]
Derivative, Notional Amount	0.0			125.0
Foreign Exchange Forward [Member]
Derivative [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax	97.0	45.0
Foreign Exchange Forward [Member] \| Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative asset	75.0			27.0
Derivative Liability	(2.0)			(20.0)
Foreign Exchange Forward [Member] \| Designated as Hedging Instrument [Member] \| Assets [Member]
Derivative [Line Items]
Derivative, Notional Amount	2,383.0			766.0
Foreign Exchange Forward [Member] \| Designated as Hedging Instrument [Member] \| Liability [Member]
Derivative [Line Items]
Derivative, Notional Amount	301.0			980.0
Foreign Exchange Forward [Member] \| Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative asset	73.0			91.0
Derivative Liability	(19.0)			(10.0)
Foreign Exchange Forward [Member] \| Not Designated as Hedging Instrument [Member] \| Assets [Member]
Derivative [Line Items]
Derivative, Notional Amount	1,177.0			2,342.0
Foreign Exchange Forward [Member] \| Not Designated as Hedging Instrument [Member] \| Liability [Member]
Derivative [Line Items]
Derivative, Notional Amount	772.0			1,173.0
Foreign Exchange Contract [Member] \| Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative asset	22.0			14.0
Derivative Liability	(8.0)			(9.0)
Foreign Exchange Contract [Member] \| Not Designated as Hedging Instrument [Member] \| Assets [Member]
Derivative [Line Items]
Derivative, Notional Amount	1,522.0			2,482.0
Foreign Exchange Contract [Member] \| Not Designated as Hedging Instrument [Member] \| Liability [Member]
Derivative [Line Items]
Derivative, Notional Amount	1,597.0			$ 2,235.0
Euro Member Countries, Euro \| Foreign Exchange Forward [Member] \| Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Notional Amount	1,700.0
Japan, Yen \| Cross Currency Interest Rate Contract [Member] \| Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Notional Amount	400.0
Japan, Yen \| Foreign Exchange Forward [Member] \| Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Notional Amount	1,200.0
Cost of Sales [Member] \| Interest Rate Swap [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0.0	0.0
Cost of Sales [Member] \| Cross Currency Interest Rate Contract [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0.0	0.0
Cost of Sales [Member] \| Foreign Exchange Forward [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net	(23.0)	(30.0)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(20.0)	(30.0)
Cost of Sales [Member] \| Foreign Exchange Contract [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net	0.0
Cost of Sales [Member] \| Forward Starting Interest Rate Swap Contracts [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net		0.0
Other Income [Member] \| Interest Rate Swap [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net	(7.0)	(5.0)
Other Income [Member] \| Cross Currency Interest Rate Contract [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net	(2.0)	(2.0)
Other Income [Member] \| Foreign Exchange Forward [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net	(76.0)	9.0
Other Income [Member] \| Foreign Exchange Contract [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net	$ (9.0)
Other Income [Member] \| Forward Starting Interest Rate Swap Contracts [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net		$ 35.0
London Interbank Offered Rate (LIBOR) [Member]
Derivative [Line Items]
Derivative, Variable Interest Rate	1.00%		1.00%

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Debt) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Debt Instrument [Line Items]
Short-term Bank Loans and Notes Payable	$ 345		$ 351
Current portion of long-term debt	3,261		2,763
Other Short-term Borrowings	256		232
Bank drafts and short-term borrowings	3,862		3,346
Debt Instrument, Face Amount	44,310		44,335
Adjustments to Principal Value, Unamortized basis adjustment from swap terminations	168		175
Debt Instrument, Unamortized Discount	(271)		(280)
Debt Instrument, Unamortized Premium	1,873		1,914
Total Debt	46,105		46,150
Long-term debt	42,844		43,387
Long-term debt, fair value	51,900		50,700
Interest payments	491	$ 57
Interest Rate Swap [Member]
Debt Instrument [Line Items]
Derivative Liability	25		$ 6
1.600% Notes Due 2019 [Member]
Debt Instrument [Line Items]
Repayments of Notes Payable		$ 750
Interest rate on matured debt		1.60%
1.750% Notes Due 2019 [Member]
Debt Instrument [Line Items]
Repayments of Notes Payable		$ 500
Interest rate on matured debt		1.75%
$2.0 Billion Revolving Credit Facility Expiring in January 2020 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	2,000
$1.5 Billion Revolving Credit Facility Expiring in September 2023 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	1,500
$1.5 Billion Revolving Credit Facility Expiring in July 2024 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	1,500
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	6,000
Revolving Credit Facility [Member] \| $1.0 Billion Revolving Credit Facility Expiring in January 2022 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,000

RECEIVABLES (Details) $ in Millions	3 Months Ended
RECEIVABLES (Details) $ in Millions	Mar. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2019 USD ($)
Account Receivables [Line Items]
Trade receivables	$ 7,660		$ 6,888
Charge-Backs and Cash Discounts	(437)		(391)
Less allowances	(23)		(21)
Net trade receivables	7,200		6,476
Other	1,090		1,209
Receivables	8,290		$ 7,685
Non-U.S. receivables sold on a nonrecourse basis	$ 180	$ 174
Number Of Largest Pharmaceutical Wholesalers	3
Customer Concentration Risk [Member]
Account Receivables [Line Items]
Percent of aggregate total trade receivables due from three pharmaceutical wholesalers	55.00%		50.00%

INVENTORIES (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Inventory, Finished Goods, Net of Reserves	$ 1,283	$ 2,227
Inventory, Work in Process, Net of Reserves	2,651	3,267
Inventory, Raw Materials and Supplies, Net of Reserves	164	172
Total inventories	4,098	5,666
Inventories	2,836	4,293
Inventories - other assets	1,262	1,373
Inventory purchase price fair value adjustment [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	$ 2,100	$ 3,500

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Land	$ 194		$ 187
Buildings and Improvements, Gross	5,848		6,336
Machinery and Equipment, Gross	3,055		3,157
Construction in Progress, Gross	456		527
Gross property, plant and equipment	9,553		10,207
Less accumulated depreciation	(3,441)		(3,955)
Property, plant and equipment	6,112		$ 6,252
Depreciation expense	$ 170	$ 133

GOODWILL AND OTHER INTANGIBLE ASSETS (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill		$ 22,452		$ 22,488
Gross other intangible assets		68,072		68,106
Less: accumulated amortization		(6,406)		(4,137)
Other intangible assets		61,666		63,969
Acquired Developed Product Rights Reclassified From IPRD		3,600
Amortization expense		2,300	$ 53
Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net		482		482
Technology-Based Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net		50,427		46,827
Capitalized Software, Intangible Asset [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net		1,263		1,297
In Process Research and Development [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
In-process research and development		$ 15,900		$ 19,500
Minimum [Member] \| Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		5 years
Minimum [Member] \| Technology-Based Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		3 years
Minimum [Member] \| Capitalized Software, Intangible Asset [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		3 years
Maximum [Member] \| Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		15 years
Maximum [Member] \| Technology-Based Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		15 years
Maximum [Member] \| Capitalized Software, Intangible Asset [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		10 years
Forecast [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Developed Product Rights Reclassified From IPRD	$ 7,500

SUPPLEMENTAL FINANCIAL INFORMATION Other Current Assets (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Other Current Assets [Abstract]
Prepaid Taxes	$ 999	$ 754
Research and Development	445	410
Other Prepaid Expense, Current	961	819
Other current assets	$ 2,405	$ 1,983

SUPPLEMENTAL FINANCIAL INFORMATION Other Non-Current Assets (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Other Non-Current Assets [Abstract]
Equity investments	$ 3,144	$ 3,405
Inventories - other assets	1,262	1,373
Operating Lease, Right-of-Use Asset	724	704
Assets for Plan Benefits, Defined Benefit Plan	189	456
Restricted Cash, Noncurrent	342	390
Other Assets, Miscellaneous, Noncurrent	285	276
Other non-current assets	5,946	$ 6,604
Restricted Cash	$ 429

Other Current Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Other Liabilities, Current [Abstract]
Accrued rebates and returns	$ 4,407	$ 4,275
Accrued Income Taxes, Current	1,996	1,517
Employee-related Liabilities, Current	678	1,457
Accrued Research And Development	1,308	1,324
Dividends Payable, Current	1,037	1,025
Accrued Interest	393	493
Accrued Royalties, Current	328	418
Operating Lease, Liability, Current	136	133
Other Accrued Liabilities, Current	2,018	1,871
Other current liabilities	$ 12,301	$ 12,513

SUPPLEMENTAL FINANCIAL INFORMATION Other Non-Current Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2020	Dec. 31, 2019
Accrued Income Taxes, Noncurrent	$ 5,364	$ 5,368
Non-current pension liabilities	841	725
Operating Lease, Liability, Noncurrent	688	672
Deferred Income, Noncurrent	394	424
Deferred Compensation Liability, Classified, Noncurrent	254	287
Other Accrued Liabilities, Noncurrent	298	350
Other non-current liabilities	10,701	10,101
Contingent Value Rights [Member]
Business Combination, Contingent Consideration, Liability	$ 2,862	$ 2,275

EQUITY (Changes in Equity) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions		3 Months Ended
	Jan. 01, 2019	Mar. 31, 2020	Mar. 31, 2019	Jan. 01, 2020
Common Stock, Dividends, Per Share, Declared		$ 0.45	$ 0.41
Stock Repurchase Program, Remaining Authorized Repurchase Amount		$ 5,900.0		$ 1,000.0
Stock Repurchase Program, Authorized Amount		5,000.0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common Stock, Value, Issued, Balance at Beginning of Period		292.0
Common Stock, Value, Issued, Balance at End of Period		292.0
Capital in Excess of Par Value of Stock, Balance at Beginning of Period		43,709.0
Capital in Excess of Par Value of Stock, Balance at End of Period		43,254.0
Accumulated Other Comprehensive Loss, Balance at Beginning of Period		(1,520.0)
Other Comprehensive Income/(Loss)		(29.0)	$ 118.0
Accumulated Other Comprehensive Loss, Balance at End of Period		(1,549.0)
Retained Earnings, Balance at Beginning of Period		34,474.0
Net Earnings Attributable to BMS		(775.0)	1,710.0
Retained Earnings, Balance at End of Period		$ 32,671.0
Stock repurchase program, Shares		1.4
Cost of Treasury Stock, Balance at Beginning of Period		$ (25,357.0)
Stock Repurchased During Period, Value		(81.0)
Cost of Treasury Stock, Balance at End of Period		(24,757.0)
Noncontrolling interest, Balance at Beginning of Period		100.0
Net Income (Loss) Attributable to Noncontrolling Interest		(9.0)	$ (5.0)
Noncontrolling interest, Balance at End of Period		$ 66.0
Common Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common Stock, Shares Issued, Balance at Beginning of Period	2,208.0	2,923.0	2,208.0
Common Stock, Shares Issued, Balance at End of Period		2,923.0	2,208.0
Common Stock, Value, Issued, Balance at Beginning of Period	$ 221.0	$ 292.0	$ 221.0
Common Stock, Value, Issued, Balance at End of Period		292.0	221.0
Capital in Excess of Par Value of Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Capital in Excess of Par Value of Stock, Balance at Beginning of Period	2,081.0	43,709.0	2,081.0
Stockholders' Equity, Other		(455.0)	22.0
Capital in Excess of Par Value of Stock, Balance at End of Period		43,254.0	2,103.0
Accumulated Other Comprehensive Loss
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accumulated Other Comprehensive Loss, Balance at Beginning of Period	(2,762.0)	(1,520.0)	(2,762.0)
Other Comprehensive Income/(Loss)		(29.0)	118.0
Accumulated Other Comprehensive Loss, Balance at End of Period		(1,549.0)	(2,644.0)
Retained Earnings [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Retained Earnings, Balance at Beginning of Period	34,065.0	34,474.0	34,065.0
Net Earnings Attributable to BMS		(775.0)	1,710.0
Cash dividends declared		(1,028.0)	(671.0)
Retained Earnings, Balance at End of Period	$ 34,070.0	$ 32,671.0	$ 35,109.0
Treasury Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Shares, Balance at Beginning of Period	576.0	672.0	576.0
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation		(13.0)	(4.0)
Treasury Stock, Shares, Balance at End of Period		660.0	572.0
Cost of Treasury Stock, Balance at Beginning of Period	$ (19,574.0)	$ (25,357.0)	$ (19,574.0)
Employee stock compensation plans, Cost		681.0	3.0
Cost of Treasury Stock, Balance at End of Period		(24,757.0)	(19,571.0)
Noncontrolling Interest [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Noncontrolling interest, Balance at Beginning of Period	96.0	100.0	96.0
Net Income (Loss) Attributable to Noncontrolling Interest		9.0	5.0
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders		(43.0)	(2.0)
Noncontrolling interest, Balance at End of Period		$ 66.0	$ 99.0
Accounting Standards Update 2016-02 [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of an accounting change on retained earnings	$ 5.0

EQUITY (Other Comprehensive Income/(Loss)) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Other Comprehensive Income (Loss), before Tax [Abstract]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax	$ 97	$ 45
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax	(20)	(30)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax	77	15
Pension and postretirement benefits - Actuarial gains/(losses), Pre-tax	8	(2)
Pension and postretirement benefits - Amortization, Pre-tax	9	17
Pension and postretirement benefits - Curtailments and settlements, Pre-Tax	2	49
Pension and postretirement benefits, Pre-tax	19	64
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments and Tax	2	23
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax	0	3
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax	2	26
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax	(110)	32
Other Comprehensive Income/(Loss), Pre-tax	(12)	137
Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax	(10)	(5)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax	3	4
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax	(7)	(1)
Pension and postretirement benefits - Actuarial gains/(losses), Tax	(2)	0
Pension and postretirement benefits - Amortization, Tax	(1)	(4)
Pension and postretirement benefits - Curtailments and settlements, Tax	0	(11)
Pension and postretirement benefits, Tax	(3)	(15)
Other Comprehensive Income (Loss), Available-for-sale Securities, before Reclassification Adjustments, Tax	(1)	0
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax	0	0
Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax	(1)	0
Foreign currency translation, Tax	(6)	(3)
Other comprehensive income/(loss), Tax	(17)	(19)
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	87	40
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax	(17)	(26)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax	70	14
Pension and postretirement benefits - Actuarial gains/(losses), After tax	6	(2)
Pension and postretirement benefits - Amortization, After tax	8	13
Pension and postretirement benefits - Curtailments and settlements, After tax	2	38
Pension and postretirement benefits, After tax	16	49
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments, after Tax	1	23
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax	0	3
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax	1	26
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(116)	29
Other Comprehensive Income/(Loss)	(29)	$ 118
Derivatives qualifying as cash flow hedges	89		$ 19
Pension and postretirement benefits	(883)		(899)
Available-for-sale securities	7		6
Foreign currency translation	(762)		(646)
Accumulated other comprehensive loss	$ (1,549)		$ (1,520)

PENSION AND POSTRETIREMENT BENEFIT PLANS (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Net periodic benefit cost/(credit)	$ (4)	$ 44
Non-current pension liabilities	841		$ 725
Defined contribution plan expense	85	40
Pension Assets Transfer	381
Reversion excise tax	76	0
Pension Benefits [Member]
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Service cost - benefits earned during the period	12	7
Interest cost on projected benefit obligation	8	44
Expected return on plan assets	(23)	(64)
Amortization of prior service credits	(1)	(1)
Amortization of net actuarial (gain)/loss	11	18
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment	2	49
Net periodic benefit cost/(credit)	9	$ 53
Non-current pension liabilities	$ 560		$ 569

EMPLOYEE STOCK BENEFIT PLANS Share-based Payment Arrangement, Cost by Plan (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Share-based Payment Arrangement, Expense	$ 210	$ 53
Share-based Payment Arrangement, Expense, Tax Benefit	46	10
Proceeds and Excess Tax Benefit from Share-based Compensation	23	2
Cost of Sales [Member]
Share-based Payment Arrangement, Expense	10	4
Selling, General and Administrative Expenses [Member]
Share-based Payment Arrangement, Expense	88	30
Research and Development Expense [Member]
Share-based Payment Arrangement, Expense	94	19
Other Income [Member]
Share-based Payment Arrangement, Expense	18	$ 0
Celgene [Member]
Share-based Payment Arrangement, Expense	123
Share-based Payment Arrangement, Accelerated Cost	18
Contingent Value Rights [Member] \| Share-based Payment Arrangement, Option [Member] \| Celgene [Member]
Share-based Payment Arrangement, Expense	$ 9

EMPLOYEE STOCK BENEFIT PLANS Schedule Of Share Based Compensation Additional Information (Details) shares in Millions	3 Months Ended
	Mar. 31, 2020 $ / shares shares
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period \| shares	12.5
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares	$ 53.63
Market share units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period \| shares	0.9
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares	$ 53.88
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period \| shares	1.4
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value \| $ / shares	$ 55.66

EMPLOYEE STOCK BENEFIT PLANS Share-based Payment Arrangement, Nonvested Award, Cost (Details) $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($)
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 92
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	1 year 10 months 24 days
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 1,397
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years 10 months 24 days
Market share units [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 77
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	3 years 4 months 24 days
Performance Shares [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 135
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years 1 month 6 days

LEGAL PROCEEDINGS AND CONTINGENCIES (Details)	3 Months Ended
LEGAL PROCEEDINGS AND CONTINGENCIES (Details)	Mar. 31, 2020 USD ($) lawsuits
Anti-PD-1 Antibody Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Loss Contingency, Patents Allegedly Infringed, Number	6
Eliquis Patent Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Loss Contingency, Patents Allegedly Infringed, Number	2
Loss Contingency, Number of Plaintiffs	25
Plavix Australia Intellectual Property [Member] \| Australia, Dollars
Legal Proceedings And Contingencies [Line Items]
Loss contingency, Estimate of possible loss	$ 449,000,000
Plavix Australia Intellectual Property [Member] \| United States of America, Dollars
Legal Proceedings And Contingencies [Line Items]
Loss contingency, Estimate of possible loss	$ 276,000,000
Abilify Product Liability [Member]
Legal Proceedings And Contingencies [Line Items]
Loss Contingency, Pending Claims, Number \| lawsuits	212
Byetta Product Liability Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Loss Contingency, Pending Claims, Number \| lawsuits	584
Securities Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Loss Contingency, Pending Claims, Number \| lawsuits	2
Cercla Matters [Member]
Legal Proceedings And Contingencies [Line Items]
Loss contingency, Estimate of possible loss	$ 69,400,000
Upfront, milestone and other licensing receipts [Member] \| CAR T Kite Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Loss contingency, Estimate of possible loss	585,000,000
Royalty [Member] \| CAR T Kite Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Loss contingency, Estimate of possible loss	$ 0.276